https://www.farmacovigilanzasardegna.it/2020/10/29/approccio-diagnostico-alle-reazioni-da-ipersensibilita-a-mezzi-di-contrasto-iodato-esperienza-di-un-centro-italiano/ 2020-11-02T09:07:22+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/skin-prick-test.png https://www.farmacovigilanzasardegna.it/2020/10/29/nota-informativa-importante-su-esbriet-pirfenidone-29-ottobre-2020/ 2020-11-02T11:35:55+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2019/11/aifa-n.jpg https://www.farmacovigilanzasardegna.it/2020/10/29/nota-informativa-importante-su-fluorochinoloni-ad-uso-sistemico-ed-inalatorio-29-ottobre-2020/ 2020-11-02T11:38:22+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/11/10/nota-informativa-importante-su-gilenya-fingolimod-10-novembre-2020/ 2020-11-10T12:11:41+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/11/06/ototossicita-come-reazione-avversa-a-farmaci-unanalisi-del-segnale-basata-sui-dati-italiani/ 2020-11-11T10:53:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/11/ear.png https://www.farmacovigilanzasardegna.it/2020/11/11/monitoraggio-terapeutico-di-bambini-e-adolescenti-trattati-con-aripiprazolo/ 2020-11-11T11:45:28+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/11/drop-pink-chemicals-into-beaker-scaled.jpg https://www.farmacovigilanzasardegna.it/2020/11/13/terapie-avanzate-car-t-dal-laboratorio-al-paziente/ 2020-11-13T10:58:47+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/11/copertina-libro-con-loghi.png https://www.farmacovigilanzasardegna.it/2020/11/13/ipotensione-ortostatica-correlata-ai-farmaci-oltre-i-farmaci-antipertensivi/ 2020-11-13T11:22:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/11/blood-pressure-1006790_1920.jpg https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/11/image.png https://www.farmacovigilanzasardegna.it/2020/11/12/nota-informativa-importante-su-tecfidera-dimetilfumarato-12-novembre-2020/ 2020-11-13T12:26:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/11/18/settimana-mondiale-di-consapevolezza-sugli-antibiotici/ 2020-11-18T12:55:15+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/11/who-2020-waaw-social-still-5.jpg https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/11/who-2020-waaw-social-still-2.jpg https://www.farmacovigilanzasardegna.it/2020/11/13/comunicazione-ema-su-ulipristal-acetato-13-novembre-2020/ 2020-11-19T11:43:05+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/11/13/nitrosammine-ema-allinea-le-raccomandazioni-per-i-sartani-a-quelle-per-le-altre-classi-di-medicinali-13-novembre-2020/ 2020-11-19T11:52:21+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/11/16/ema-avvia-la-revisione-ciclica-del-vaccino-a-base-di-mrna-per-covid-19-di-moderna-biotech-spain-s-l-16-novembre-2020/ 2020-11-19T12:02:22+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/11/20/utilizzo-di-nimesulide-durante-il-primo-trimestre-di-gravidanza-e-rischio-di-malformazioni-congenite-uno-studio-di-popolazione-italiano/ 2020-11-20T12:38:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/11/pregnancy.png https://www.farmacovigilanzasardegna.it/2020/11/19/considerazioni-ema-sullapprovazione-dei-vaccini-per-covid-19-19-novembre-2020/ 2020-11-24T09:10:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/11/23/aggiornamento-su-remdesivir-ema-valutera-i-nuovi-dati-dello-studio-solidarity-23-novembre-2020/ 2020-11-24T09:13:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/11/27/la-psicofarmacologia-nella-gestione-dei-pazienti-con-covid-19/ 2020-11-27T08:33:38+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/11/pexels-anna-shvets-3786157-scaled.jpg https://www.farmacovigilanzasardegna.it/2020/11/27/impurita-di-nitrosamina-in-sartani-ranitidina-nizatidina-e-metformina-aggiornamenti-normativi-e-metodologie-analitiche-per-il-rilevamento/ 2020-11-27T08:58:55+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/11/lab-217043_1280.jpg https://www.farmacovigilanzasardegna.it/2020/11/27/aggiornamento-della-comunicazione-ai-crfv-rlfv-sulla-gestione-delle-segnalazioni-di-sospette-reazioni-avverse-relative-a-medicinali-utilizzati-nella-terapia-del-covid-19-27-novembre-2020/ 2020-12-01T08:14:47+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/12/04/raccomandazioni-del-pharmacovigilance-risk-assessment-committee-prac-dellema-per-il-mese-di-novembre/ 2020-12-04T08:29:59+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/12/04/cardiotossicita-associata-alla-gemcitabina-revisione-della-letteratura-e-studio-di-farmacovigilanza/ 2020-12-04T11:45:15+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/12/analysis-4224502_1920.jpg https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/12/image.png https://www.farmacovigilanzasardegna.it/2020/12/10/segnalazione-di-sospette-reazioni-avverse-ai-medicinali-nei-pazienti-con-covid-19/ 2020-12-10T11:33:18+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/12/ADR-reporting-Operatori-Sanitari_Infografica-2.pdf https://www.farmacovigilanzasardegna.it/2020/12/01/nota-informativa-importante-su-gliolan-acido-5-aminolevulinico-5-ala-1-dicembre-2020/ 2020-12-11T08:05:47+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/12/01/ema-avvia-la-revisione-ciclica-di-ad26-cov2-s-vaccino-per-covid-19-di-janssen-1-dicembre-2020/ 2020-12-11T08:10:00+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/12/01/ema-riceve-la-domanda-di-aic-subordinata-a-condizioni-per-il-vaccino-covid-19-moderna-1-dicembre-2020/ 2020-12-11T08:23:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/12/01/ema-riceve-la-domanda-di-aic-subordinata-a-condizioni-per-bnt162b2-vaccino-per-covid-19-basato-su-mrna-1-dicembre-2020/ 2020-12-11T08:26:49+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/12/09/nota-informativa-importante-su-medicinali-a-base-di-suxametonio-cloruro-9-dicembre-2020/ 2020-12-11T08:29:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/12/11/esketamina-una-revisione-sui-dati-di-efficacia-e-sicurezza/ 2020-12-11T12:44:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/12/pexels-anna-shvets-3683098-scaled.jpg https://www.farmacovigilanzasardegna.it/2020/12/18/aifa-pubblica-il-rapporto-vaccini-2019/ 2020-12-18T10:40:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/12/15/aggiornamento-sulla-valutazione-della-domanda-di-autorizzazione-allimmissione-in-commercio-del-vaccino-bnt162b2-di-biontech-e-pfizer-15-dicembre-2020/ 2020-12-18T10:43:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/12/15/nota-informativa-importante-su-metamizolo-15-dicembre-2020/ 2020-12-18T10:48:00+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/12/17/nota-informativa-importante-su-epaclob-17-dicembre-2020/ 2020-12-18T10:50:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/12/18/aggiornamento-sulla-valutazione-della-domanda-di-autorizzazione-allimmissione-in-commercio-del-vaccino-a-mrna-1273-per-covid-19-di-moderna-18-dicembre-2020/ 2020-12-21T11:32:47+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/12/21/ema-raccomanda-lautorizzazione-nellue-del-primo-vaccino-covid-19-21-dicembre-2020/ 2020-12-22T12:46:42+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/12/22/nota-informativa-importante-su-nubriveo-brivaracetam-22-dicembre-2020/ 2020-12-22T12:48:50+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/12/23/nota-informativa-importante-su-zerbaxa-23-dicembre-2020/ 2020-12-28T08:27:52+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/12/23/nota-informativa-importante-su-kaletra-lopinavir-ritonavir-23-dicembre-2020/ 2020-12-28T08:30:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/12/30/nota-informativa-importante-su-epaclob-clobazam-30-dicembre-2020/ 2021-01-04T08:01:37+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/12/31/aggiornamento-sulla-revisione-ciclica-del-vaccino-covid-19-di-astrazeneca-31-dicembre-2020/ 2021-01-04T08:05:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/01/08/sicurezza-dei-vaccini-nei-bambini-e-nella-popolazione-generale/ 2021-01-08T11:16:04+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/close-up-picture-docter-s-hands-holding-hypodermic-syringe-scaled.jpg https://www.farmacovigilanzasardegna.it/2021/01/08/position-paper-dellaccedemia-europea-di-allergologia-sulle-reazioni-allergiche-a-vaccino-pfizer-biontech-per-covid-19/ 2021-01-11T11:59:59+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/vaccine.png https://www.farmacovigilanzasardegna.it/2021/01/06/ema-raccomanda-lautorizzazione-nellue-di-covid-19-vaccine-moderna-6-gennaio-2021/ 2021-01-11T12:47:34+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/01/08/dose-extra-dai-flaconcini-del-vaccino-anti-covid-19-comirnaty-8-gennaio-2021/ 2021-01-11T12:51:49+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/01/14/aifa-pubblica-le-faq-di-farmacovigilanza-su-vaccini-covid-19/ 2021-01-14T08:16:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/01/15/il-centro-regionale-di-farmacovigilanza-della-regione-sardegna-pubblica-il-bollettino-del-secondo-semestre-2020/ 2021-01-15T11:21:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/imm.png https://www.farmacovigilanzasardegna.it/2021/01/15/il-centro-regionale-di-farmacovigilanza-della-regione-sardegna-pubblica-il-report-annuale-di-attivita-del-2020/ 2021-01-15T11:21:32+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/report-attivita-1.jpg https://www.farmacovigilanzasardegna.it/2021/01/12/ema-riceve-la-domanda-di-aic-subordinata-a-condizioni-per-il-vaccino-covid-19-vaccine-astrazeneca-12-gennaio-2021/ 2021-01-19T11:50:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/01/22/dichiarazione-delle-autorita-regolatorie-dei-farmaci-sul-processo-di-approvazione-dei-vaccini-per-il-covid-19/ 2021-01-25T07:54:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/vaccine-1.png https://www.farmacovigilanzasardegna.it/2021/01/22/sicurezza-sullutilizzo-degli-anticoagulanti-orali-diretti-doac-in-gravidanza-uno-studio-retrospettivo-di-coorte/ 2021-01-26T10:06:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/lancet.jpg https://www.farmacovigilanzasardegna.it/2021/01/28/reazioni-allergiche-e-anafilattiche-a-vaccino-contro-covid-19-di-pfizer-biontech/ 2021-01-28T11:58:00+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/JAMA.jpg https://www.farmacovigilanzasardegna.it/2021/01/29/chiarimento-ema-sullintervallo-di-somministrazione-di-comirnaty/ 2021-01-29T07:37:05+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/01/29/eventi-avversi-dei-radiofarmaci-segnalati-dai-pazienti-uno-studio-prospettico-su-1002-pazienti/ 2021-01-29T08:03:04+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/images.jpg https://www.farmacovigilanzasardegna.it/2021/02/01/nota-informativa-importante-su-ulipristal-acetato-5-mg-esmya/ 2021-02-01T09:17:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/02/01/ema-raccomanda-lautorizzazione-di-covid-19-vaccine-astrazeneca-nellue/ 2021-02-01T09:23:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/02/01/primo-aggiornamento-ema-sulla-sicurezza-di-comirnaty/ 2021-02-01T09:29:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/02/01/aifa-autorizzato-vaccino-astrazeneca/ 2021-02-01T12:01:21+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/02/02/ema-avvia-la-revisione-ciclica-dellassociazione-di-anticorpi-regn-cov2-casirivimab-imdevimab/ 2021-02-02T07:42:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/02/03/nota-informativa-importante-su-eutirox-levotiroxina/ 2021-02-03T08:54:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/02/hashimotos-thyroiditis.png https://www.farmacovigilanzasardegna.it/2021/02/05/nota-informativa-importante-su-alkindi/ 2021-02-05T07:31:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/02/05/ema-avvia-la-revisione-ciclica-del-vaccino-anti-covid-19-di-novavax-nvx-cov2373/ 2021-02-05T07:34:25+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/02/05/primo-rapporto-aifa-sulla-sorveglianza-dei-vaccini-covid-19/ 2021-02-05T07:57:04+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/02/05/ema-procede-alla-revisione-dei-dati-sulluso-degli-anticorpi-monoclonali-contro-covid-19/ 2021-02-05T10:31:57+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/02/08/aifa-pubblica-parere-cts-su-anticorpi-monoclonali/ 2021-02-08T07:22:37+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/02/12/sicurezza-ed-efficacia-della-terapia-con-statine/ 2021-02-12T08:09:31+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/02/Nature_Reviews_Cardiology_logo_750_130_70-2.jpg https://www.farmacovigilanzasardegna.it/2021/02/12/efficacia-e-sicurezza-dellidrossiclorochina-nella-profilassi-del-covid-19/ 2021-02-12T08:19:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/02/plos.jpg https://www.farmacovigilanzasardegna.it/2021/02/12/nota-informativa-importante-su-talidomide-accord/ 2021-02-12T11:55:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/02/12/nota-informativa-importante-su-respreeza/ 2021-02-12T11:58:00+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/02/16/ema-avvia-la-revisione-ciclica-del-vaccino-anti-covid-19-di-curevac-cvncov/ 2021-02-16T07:22:41+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/02/16/avvio-di-una-revisione-dei-medicinali-a-base-di-amfepramone/ 2021-02-16T07:25:33+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/02/17/ema-riceve-la-domanda-di-aic-subordinata-a-condizioni-per-il-vaccino-covid-19-vaccine-janssen/ 2021-02-17T11:32:25+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/02/18/sospensione-precauzionale-della-commercializzazione-del-medicinale-per-la-talassemia-zynteglo/ 2021-02-18T09:25:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/02/18/nota-informativa-importante-su-lojuxta-lomitapide/ 2021-02-18T09:27:52+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/02/19/antistaminici-effetti-e-sicurezza-della-fexofenadina/ 2021-02-19T08:30:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/02/sneeze.png https://www.farmacovigilanzasardegna.it/2021/02/19/linee-di-indirizzo-per-la-gestione-da-parte-degli-allergologi-dei-pazienti-a-rischio-di-reazioni-allergiche-ai-vaccini-per-covid-19/ 2021-02-19T08:33:37+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/02/logo-siaaic.trasp_-1.png https://www.farmacovigilanzasardegna.it/2021/02/19/manifestazioni-cliniche-e-impatto-nella-vita-quotidiana-dellallergia-al-glicole-polietilenico-peg-in-dieci-pazienti/ 2021-02-19T08:40:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/02/hives.png https://www.farmacovigilanzasardegna.it/2021/02/23/ema-valuta-luso-di-veklury-in-pazienti-con-covid-19-che-non-necessitano-di-ossigenoterapia-supplementare/ 2021-02-23T10:27:00+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/02/26/ema-avvia-la-revisione-ciclica-di-regdanvimab-anticorpo-di-celltrion-contro-covid-19/ 2021-02-26T10:01:42+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/02/26/comunicazione-ema-adattare-i-vaccini-anti-covid-19-alle-varianti-del-sars-cov-2-orientamenti-per-i-produttori-di-vaccini/ 2021-02-26T10:17:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/02/26/lema-formula-raccomandazioni-sulluso-dellassociazione-di-anticorpi-regn-cov2-casirivimab-imdevimab/ 2021-03-02T07:34:57+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/03/02/parliamone-dialoghi-con-aifa-sulla-campagna-vaccinale/ 2021-03-02T08:53:23+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/02/26/interazioni-farmacologiche-in-pazienti-anziani-o-con-problemi-mentali/ 2021-03-02T10:02:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/03/porta-pastiglie-1.jpg https://www.farmacovigilanzasardegna.it/2021/02/26/il-litio-assunto-attraverso-lallattamento-al-seno-inibisce-lassorbimento-dello-iodio-nella-tiroide-e-la-produzione-dellormone-tiroideo-che-puo-essere-corretto-con-una-suppl/ 2021-03-02T10:53:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2020/09/20190610-litio-depressione-pleinair.jpg https://www.farmacovigilanzasardegna.it/2021/03/05/ema-avvia-la-rolling-review-del-vaccino-anti-covid-19-sputnik/ 2021-03-05T07:25:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/03/05/revisione-ema-di-regdanvimab-per-covid-19-a-sostegno-delle-decisioni-nazionali-sulluso-precoce/ 2021-03-05T07:27:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/03/08/lema-formula-raccomandazioni-sulluso-dellassociazione-di-anticorpi-bamlanivimab-etesevimab/ 2021-03-08T10:13:14+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/03/05/le-interazioni-tra-farmaci-nel-trattamento-cronico-da-virus-dellepatite-c/ 2021-03-09T12:08:59+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/03/Gray1224.png https://www.farmacovigilanzasardegna.it/2021/03/05/una-revisione-sulla-sicurezza-del-n-acetilcisteina-ad-alte-dosi-nelle-malattie-respiratorie-croniche/ 2021-03-09T12:15:02+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/03/lungs.png https://www.farmacovigilanzasardegna.it/2021/03/11/ema-avvia-la-revisione-ciclica-degli-anticorpi-di-eli-lilly-bamlanivimab-ed-etesemivab-contro-covid-19/ 2021-03-11T09:44:59+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/03/11/vaccino-covid-19-astrazeneca-la-valutazione-preliminare-del-prac-non-evidenzia-alcuna-problematica-specifica-con-il-lotto-utilizzato-in-austria/ 2021-03-11T09:47:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/03/11/ema-pubblica-il-secondo-aggiornamento-sulla-sicurezza-dei-vaccini-covid-19-comirnaty-e-moderna/ 2021-03-11T09:52:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/03/11/secondo-rapporto-aifa-sulla-sorveglianza-dei-vaccini-covid-19/ 2021-03-11T09:57:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/03/12/vaccino-covid-19-astrazeneca-il-prac-sta-investigando-casi-di-eventi-tromboembolici-i-benefici-del-vaccino-attualmente-superano-ancora-i-rischi-aggiornamento/ 2021-03-12T09:15:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/03/12/i-benefici-delle-soluzioni-contenenti-ifosfamide-continuano-a-superare-i-rischi/ 2021-03-12T12:30:18+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/03/15/avviata-una-revisione-del-medicinale-per-la-talassemia-zynteglo/ 2021-03-15T07:31:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/03/15/aifa-ingiustificato-allarme-sulla-sicurezza-del-vaccino-astrazeneca/ 2021-03-15T07:33:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/03/15/ema-raccomanda-lautorizzazione-nellue-di-covid-19-vaccine-janssen/ 2021-03-15T08:02:31+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/03/16/aifa-sospensione-precauzionale-del-vaccino-astrazeneca/ 2021-03-19T07:18:21+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/03/19/dopo-parere-ema-riprendono-le-vaccinazioni-con-astrazeneca/ 2021-03-19T07:22:08+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/03/19/nota-informativa-importante-su-zolgensma-onasemnogene-abeparvovec/ 2021-03-19T07:26:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/03/19/identificazione-e-caratterizzazione-delle-reazioni-avverse-gravi-associate-allinterazione-tra-farmaci-in-un-database-di-segnalazioni-spontanee/ 2021-03-19T10:31:18+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/03/veneto.jpg https://www.farmacovigilanzasardegna.it/2021/03/19/vaccino-covid-19-astrazeneca-i-benefici-continuano-ad-essere-superiori-ai-rischi-nonostante-un-possibile-collegamento-con-rari-casi-di-trombi-associati-a-bassi-livelli-di-piastrine-nel-sangue/ 2021-03-19T10:45:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/03/23/nota-informativa-importante-su-strimvelis/ 2021-03-23T07:45:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/03/23/ema-raccomanda-di-non-utilizzare-ivermectina-per-la-prevenzione-o-il-trattamento-di-covid-19-al-di-fuori-degli-studi-clinici/ 2021-03-23T07:48:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/03/25/vaccino-covid-19-astrazeneca-nota-informativa-sul-rischio-di-trombocitopenia-e-disturbi-della-coagulazione/ 2021-03-25T13:35:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/03/25/vaccino-covid-19-astrazeneca-aggiornamento-sulla-valutazione-in-corso-dei-casi-con-eventi-tromboembolici/ 2021-03-25T16:09:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/03/25/nota-informativa-importante-su-tecentriq-atezolizumab/ 2021-03-25T16:20:41+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/03/25/nota-informativa-importante-su-xeljanz-tofacitinib/ 2021-03-25T16:22:49+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/03/26/aumento-della-capacita-produttiva-e-della-fornitura-di-vaccini-anti-covid-19-di-astrazeneca-biontech-pfizer-e-moderna/ 2021-03-26T15:54:32+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/03/26/ema-formula-raccomandazioni-sulluso-di-regdanvimab-per-il-trattamento-di-covid-19/ 2021-03-26T15:58:06+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/03/31/ema-pubblica-un-aggiornamento-sulla-sicurezza-dei-vaccini-covid-19-comirnaty-moderna-e-astrazeneca/ 2021-03-31T08:07:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/03/31/nuova-scheda-tecnica-del-vaccino-astrazeneca-che-cambia-nome-in-vaxzevria/ 2021-03-31T11:43:38+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/04/01/reazioni-avverse-sospette-conseguenti-alluso-di-integratori-alimentari-segnalazioni-spontanee-dal-sistema-italiano-di-fitovigilanza/ 2021-04-01T06:37:25+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/04/inegratori-alimentari-funzionano-scaled.jpg https://www.farmacovigilanzasardegna.it/2021/04/01/linsonnia-nei-pazienti-anziani-raccomandazioni-per-una-migliore-gestione-farmacologica/ 2021-04-01T06:44:59+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/04/insonnia-26498603.jpg https://www.farmacovigilanzasardegna.it/2021/04/01/vaccino-astrazeneca-covid-19-continua-la-revisione-dei-casi-di-trombi-molto-rari-e-inusuali/ 2021-04-01T08:26:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/04/08/farmaci-biosimilari-in-italia-nuovi-report-dellaifa/ 2021-04-08T11:13:07+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/drug-4938120_1920.jpg https://www.farmacovigilanzasardegna.it/2021/04/08/vaccino-covid-19-astrazeneca-ema-trova-un-possibile-collegamento-con-casi-molto-rari-di-trombi-inusuali-associati-a-bassi-livelli-di-piastrine/ 2021-04-08T17:04:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/04/09/nota-informativa-importante-su-emoclot-klott-plasmaclot-uman-complex-kedcom-aimafix-kedrifix-ixed-atked-atiii-kedrion/ 2021-04-09T10:05:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/04/13/monitoraggio-anticorpi-monoclonali-per-covid-19-pubblicato-il-primo-report-aifa/ 2021-04-13T07:13:15+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/04/14/nota-informativa-importante-su-vaxzevria-covid-19-vaccine-astrazeneca/ 2021-04-14T07:15:51+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/04/15/vaccino-covid-19-astrazeneca-ema-approfondisce-ulteriormente-il-rischio-di-casi-molto-rari-di-trombi-associati-a-piastrinopenia/ 2021-04-15T07:29:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/04/16/vaccino-covid-19-janssen-continua-la-valutazione-di-casi-molto-rari-di-trombi-inusuali-associati-a-piastrinopenia/ 2021-04-16T06:38:42+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/04/16/ema-avvia-la-revisione-dellanticorpo-monoclonale-vir-7831-per-il-trattamento-dei-pazienti-con-covid-19/ 2021-04-16T07:04:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/04/16/nota-informativa-importante-su-eylea/ 2021-04-16T07:05:29+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/04/16/terzo-rapporto-aifa-sulla-sorveglianza-dei-vaccini-covid-19/ 2021-04-16T07:07:18+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/04/19/monitoraggio-anticorpi-monoclonali-per-covid-19-pubblicato-il-secondo-report/ 2021-04-19T06:58:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/04/22/vaccino-contro-il-covid-19-janssen-ema-evidenzia-un-possibile-legame-con-casi-molto-rari-di-trombi-inusuali-con-basso-livello-di-piastrine/ 2021-04-22T06:39:02+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/04/26/aumento-della-capacita-produttiva-e-della-fornitura-dei-vaccini-anti-covid-19-di-biontech-pfizer-e-moderna/ 2021-04-26T07:06:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/04/26/i-benefici-delle-soluzioni-contenenti-ifosfamide-continuano-a-superare-i-rischi-2/ 2021-04-26T07:12:49+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/04/26/vaccino-anti-covid-19-di-astrazeneca-benefici-e-rischi-nel-contesto-di-tutte-le-fasce-deta/ 2021-04-26T07:16:02+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/04/26/vaccino-bnt162b2-mrna-anti-covid-19-pfizer-studio-sulla-vaccinazione-di-massa-in-israele/ 2021-04-26T10:33:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/04/nejm-large-3x2-1.jpg https://www.farmacovigilanzasardegna.it/2021/04/27/nota-informativa-importante-sul-collegamento-tra-vaccino-covid-19-janssen-e-linsorgenza-di-trombosi-in-combinazione-con-trombocitopenia/ 2021-04-27T06:22:59+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/04/28/monitoraggio-anticorpi-monoclonali-per-covid-19-pubblicato-il-terzo-report/ 2021-04-28T06:33:59+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/04/30/interazioni-farmacologiche-dei-supplementi-naturali-in-dermatologia-una-revisione/ 2021-04-30T06:19:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/04/inegratori-alimentari-funzionano-scaled.jpg https://www.farmacovigilanzasardegna.it/2021/04/30/ema-valuta-luso-di-olumiant-in-pazienti-con-covid-19-ricoverati-in-ospedale-che-necessitano-di-ossigenoterapia-supplementare/ 2021-04-30T06:23:05+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/05/04/ema-avvia-la-valutazione-delluso-di-comirnaty-vaccino-anti-covid-19-in-soggetti-di-eta-compresa-tra-12-e-15-anni/ 2021-05-04T08:13:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/05/05/ema-avvia-la-revisione-ciclica-di-covid-19-vaccine-vero-cell-inactivated/ 2021-05-05T11:24:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/05/11/ondexxya-andexanet-alfa-interazione-con-i-test-per-il-dosaggio-dellattivita-anti-fxa/ 2021-05-11T06:25:34+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/05/11/ondexxya-andexanet-alfa-luso-di-andexanet-alfa-prima-delleparinizzazione-deve-essere-evitato/ 2021-05-11T06:27:32+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/05/11/comunicazione-aifa-sulla-gestione-delle-segnalazioni-di-mancanza-di-efficacia-nella-rete-nazionale-di-farmacovigilanza/ 2021-05-11T06:30:48+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/05/11/ema-avvia-la-revisione-ciclica-di-sotrovimab-vir-7831-contro-covid-19/ 2021-05-11T06:33:15+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/05/11/quarto-rapporto-aifa-sulla-sorveglianza-dei-vaccini-covid-19/ 2021-05-11T06:43:32+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/05/rfn.jpg https://www.farmacovigilanzasardegna.it/2021/05/21/anticorpi-monoclonali-per-il-covid-19-aifa-finanziera-4-studi-clinici/ 2021-05-21T07:07:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/05/22/monitoraggio-anticorpi-monoclonali-per-covid-19-pubblicato-il-settimo-report/ 2021-05-22T09:11:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/vaccine.png https://www.farmacovigilanzasardegna.it/2021/05/22/ema-formula-raccomandazioni-sulluso-di-sotrovimab-vir-7831-per-il-trattamento-di-covid-19/ 2021-05-22T09:13:50+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/05/22/vaxzevria-ulteriori-indicazioni-su-trombi-e-bassi-livelli-di-piastrine/ 2021-05-22T10:00:34+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/05/21/farmaci-biosimilari-in-italia-report-aifa-aggiornati-a-dicembre-2020/ 2021-05-25T07:12:05+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/05/I_Biosimilari.jpg https://www.farmacovigilanzasardegna.it/2021/05/26/medicinali-contenenti-ferro-per-via-endovenosa-chiarimenti-sulle-raccomandazioni-per-la-gestione-dei-casi-di-ipersensibilita/ 2021-05-26T06:24:48+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/05/28/aifa-pubblica-un-documento-di-approfondimento-del-gruppo-di-lavoro-emostasi-e-trombosi/ 2021-05-28T06:56:00+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/05/I_coronavirus_vaccine.jpg https://www.farmacovigilanzasardegna.it/2021/05/28/dati-insufficienti-sulluso-di-corticosteroidi-per-inalazione-per-il-trattamento-di-covid-19/ 2021-05-28T11:51:29+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/05/31/corso-ecm-per-farmacisti-farmacovigilanza-e-vaccinovigilanza-sicurezza-dei-vaccini-anti-covid-19/ 2021-05-31T11:05:34+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/05/logo_CRFVSardegna.jpg https://www.farmacovigilanzasardegna.it/2021/05/26/corso-ecm-aou-cagliari-farmacovigilanza-e-vaccinovigilanza-sicurezza-dei-vaccini-anti-covid-19/ 2021-05-31T11:06:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/05/logo_CRFVSardegna.jpg https://www.farmacovigilanzasardegna.it/2021/06/01/aifa-approva-lutilizzo-del-vaccino-comirnaty-per-la-fascia-di-eta-12-15-anni/ 2021-06-01T06:40:29+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/05/31/primo-vaccino-anti-covid-19-approvato-nellue-per-bambini-di-eta-compresa-tra-12-e-15-anni/ 2021-06-01T06:41:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/06/03/aumento-della-capacita-produttiva-per-il-vaccino-anti-covid-19-di-biontech-pfizer/ 2021-06-03T09:41:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/06/03/nota-informativa-importante-su-inomax-ossido-di-azoto-no/ 2021-06-03T09:45:22+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/06/03/vaxzevria-covid-19-vaccine-astrazeneca-rischio-di-insorgenza-di-trombosi-in-combinazione-con-trombocitopenia-aggiornamento/ 2021-06-03T09:48:57+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/06/07/raccomandazioni-di-assistenza-clinica-per-la-gestione-di-una-sospetta-sindrome-trombotica-associata-a-trombocitopenia/ 2021-06-07T15:28:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/06/09/ema-valuta-luso-di-covid-19-vaccine-moderna-in-soggetti-di-eta-compresa-tra-12-e-17-anni/ 2021-06-09T10:31:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/06/10/nota-informativa-importante-su-venclyxto%e2%96%bc-venetoclax-compresse-rivestite-con-film/ 2021-06-10T11:04:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/06/11/quinto-rapporto-aifa-sulla-sorveglianza-dei-vaccini-covid-19/ 2021-06-11T09:01:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/06/05_Rap_Vax_COVID-19_600x400.jpg https://www.farmacovigilanzasardegna.it/2021/06/14/vaccini-covid-19-aggiornamento-sulla-valutazione-in-corso-dei-casi-di-miocardite-e-pericardite/ 2021-06-14T07:03:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/06/14/covid-19-vaccine-janssen-le-autorita-europee-adottano-misure-per-salvaguardare-la-qualita-del-vaccino/ 2021-06-14T07:05:45+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/06/14/vaxzevria-lema-ne-sconsiglia-luso-in-persone-con-storia-di-sindrome-da-aumentata-permeabilita-capillare/ 2021-06-14T07:07:06+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/06/15/aifa-approva-la-vaccinazione-mista-per-i-soggetti-under-60-che-abbiano-ricevuto-una-prima-dose-di-vaxzevria/ 2021-06-15T10:25:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/05/I_coronavirus_vaccine.jpg https://www.farmacovigilanzasardegna.it/2021/06/16/nota-informativa-importante-su-cabazitaxel/ 2021-06-16T10:50:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/06/18/utilizzo-di-tocilizumab-per-la-terapia-dei-pazienti-affetti-da-covid-19/ 2021-06-18T11:11:05+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/06/23/vaxzevria-covid-19-vaccine-astrazeneca-controindicazione-negli-individui-con-pregressa-sindrome-da-perdita-capillare/ 2021-06-23T09:13:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/06/28/lema-avvia-la-revisione-dellansiolitico-stresam-etifoxina/ 2021-06-28T08:37:32+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/07/02/associazione-tra-lesposizione-prenatale-agli-oppioidi-e-gli-esiti-del-neurosviluppo-nella-prima-infanzia-uno-studio-retrospettivo-di-coorte/ 2021-07-02T09:45:14+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2019/01/logo_DrugSafety.jpg https://www.farmacovigilanzasardegna.it/2021/07/02/profilo-di-sicurezza-del-vaccino-zoster-ricombinante-adiuvato-in-popolazioni-immunocompromesse-una-panoramica-di-sei-esperimenti/ 2021-07-02T09:48:20+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/vaccine-1.png https://www.farmacovigilanzasardegna.it/2021/07/06/nota-informativa-importante-su-xeljanz-tofacitinib-2/ 2021-07-06T11:26:37+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/07/07/sicurezza-ed-efficacia-del-tolcapone-nella-malattia-di-parkinson-revisione-sistematica/ 2021-07-07T11:51:33+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/07/pd.png https://www.farmacovigilanzasardegna.it/2021/07/09/modelli-di-utilizzo-efficacia-e-sicurezza-dei-mezzi-di-contrasto-al-gadolinio-uno-studio-osservazionale-multicentrico-prospettico-europeo/ 2021-07-09T06:46:22+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/07/tt.jpg https://www.farmacovigilanzasardegna.it/2021/07/09/sesto-rapporto-aifa-sulla-sorveglianza-dei-vaccini-covid-19/ 2021-07-09T11:51:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/07/12/lema-sconsiglia-luso-del-vaccino-janssen-covid-19-in-persone-con-pregressa-sindrome-da-perdita-capillare/ 2021-07-12T06:32:58+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/07/09/ema-non-rileva-alcuna-prova-che-colleghi-il-vettore-virale-di-zynteglo-al-cancro-del-sangue/ 2021-07-12T06:34:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/07/16/aggiornamento-ema-ecdc-su-covid-19-cicli-di-vaccinazione-completi-fondamentali-per-la-massima-protezione/ 2021-07-16T06:21:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2017/03/ECDC.jpg https://www.farmacovigilanzasardegna.it/2021/07/16/nota-informativa-importante-su-champix-varenicline/ 2021-07-16T06:22:51+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/07/16/nota-informativa-importante-su-prepidil-e-propess-dinoprostone/ 2021-07-16T06:26:31+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/07/12/comirnaty-e-spikevax-possibile-collegamento-a-casi-molto-rari-di-miocardite-e-pericardite/ 2021-07-19T07:16:02+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/07/19/covid-19-vaccine-janssen-controindicazione-negli-individui-con-pregressa-sindrome-da-perdita-capillare-e-aggiornamento-relativo-alla-sindrome-trombotica-trombocitopenica/ 2021-07-19T07:18:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/07/19/vaccini-a-mrna-anti-covid-19-comirnaty-e-spikevax-rischio-di-miocardite-e-di-pericardite/ 2021-07-19T07:20:44+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/07/20/ema-avvia-la-valutazione-di-kineret-per-il-trattamento-di-pazienti-adulti-con-covid-19-a-maggiore-rischio-di-insufficienza-respiratoria-severa/ 2021-07-20T07:36:53+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/07/22/ema-avvia-la-revisione-ciclica-del-vaccino-anti-covid-19-vidprevtyn/ 2021-07-22T06:22:44+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/07/23/il-chmp-approva-la-revisione-che-non-trova-alcun-legame-tra-il-vettore-virale-in-zynteglo-e-il-cancro-del-sangue/ 2021-07-23T15:05:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/07/23/vaccino-anti-covid-19-spikevax-approvato-nellue-per-bambini-di-eta-compresa-tra-12-e-17-anni/ 2021-07-23T15:06:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/07/23/vaccino-covid-19-janssen-la-sindrome-di-guillain-barre-aggiunta-alle-informazioni-sul-prodotto-come-effetto-indesiderato-molto-raro/ 2021-07-23T15:07:37+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/08/17/aggiornamento-ecdc-ema-su-covid-19/ 2021-08-17T09:37:08+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2017/03/ECDC.jpg https://www.farmacovigilanzasardegna.it/2021/08/17/ema-valuta-luso-di-roactemra-in-pazienti-adulti-ricoverati-in-ospedale-con-covid-19-grave/ 2021-08-17T09:38:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/08/25/aumento-della-capacita-produttiva-dei-vaccini-anti-covid-19-comirnaty-biontech-pfizer-e-spikevax-moderna/ 2021-08-25T06:54:23+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/08/26/dopo-reazioni-avverse-gravi-a-carico-della-sfera-coagulativa-con-prima-dose-vaxzevria-possibile-richiamo-con-vaccino-a-m-rna-anche-negli-ultra-sessantenni/ 2021-08-26T07:59:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/04/primula.png https://www.farmacovigilanzasardegna.it/2021/08/27/inibitori-dei-check-point-immunitari-e-cardiotossicita-unanalisi-delle-segnalazioni-spontanee-dalla-banca-dati-eudravigilance/ 2021-08-27T11:28:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2019/01/logo_DrugSafety.jpg https://www.farmacovigilanzasardegna.it/2021/08/27/remdesivir-nella-pandemia-da-covid-19-unanalisi-delle-segnalazioni-spontanee-in-vigibase-durante-il-2020/ 2021-08-27T11:36:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/08/upp.jpg https://www.farmacovigilanzasardegna.it/2021/08/31/bollettino-di-farmacovigilanza-della-sardegna-i-semestre-2021/ 2021-08-31T07:35:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/04/primula.png https://www.farmacovigilanzasardegna.it/2021/09/02/considerazioni-ecdc-ema-su-dosi-aggiuntive-e-di-richiamo-dei-vaccini-anti-covid-19/ 2021-09-02T13:14:49+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2020/02/loco_ECDC.jpg https://www.farmacovigilanzasardegna.it/2021/09/07/ema-valuta-i-dati-sulla-dose-di-richiamo-del-vaccino-anti-covid-19-comirnaty/ 2021-09-07T07:34:07+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/09/09/sicurezza-del-vaccino-pfizer-bnt-in-un-contesto-nazionale/ 2021-09-09T07:10:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/04/nejm-large-3x2-1.jpg https://www.farmacovigilanzasardegna.it/2021/09/10/aumento-della-capacita-produttiva-per-il-vaccino-anti-covid-19-di-biontech-pfizer-2/ 2021-09-10T06:12:14+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/09/10/parere-della-commissione-tecnico-scientifica-di-aifa-sulla-somministrazione-di-dosi-aggiuntive-di-vaccini-contro-il-covid-19/ 2021-09-10T06:16:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/09/13/ottavo-rapporto-aifa-sulla-sorveglianza-dei-vaccini-covid-19/ 2021-09-13T08:27:49+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/08/31/aifa-pubblica-la-nuova-nota-99-per-la-prescrizione-dei-farmaci-per-la-bpco/ 2021-09-14T06:17:57+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/08/I_terapia.jpg https://www.farmacovigilanzasardegna.it/2021/09/14/aifa-vaccini-influenzali-per-la-stagione-2021-2022/ 2021-09-14T06:28:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/09/20/imbruvica-ibrutinib-nuovo-segnale-di-sicurezza-sulluso-in-combinazione-con-rituximab-e-ace-inibitori/ 2021-09-20T08:57:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/09/23/vaccini-anti-covid-19-aifa-pubblica-lelenco-dei-principali-farmaci-ad-attivita-immunosoppressiva/ 2021-09-23T06:22:05+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/09/I_vaccino_07.jpg https://www.farmacovigilanzasardegna.it/2021/09/28/nota-informativa-importante-su-roactemra-tocilizumab/ 2021-09-28T13:51:00+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/09/30/nota-informativa-importante-su-champix-varenicline-2/ 2021-09-30T09:41:55+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/10/05/lema-avvia-una-revisione-del-rischio-di-meningioma-con-i-medicinali-contenenti-nomegestrolo-o-clormadinone/ 2021-10-05T06:52:18+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/10/05/lema-riceve-la-domanda-di-autorizzazione-allimmissione-in-commercio-per-regkirona-regdanvimab-per-il-trattamento-di-pazienti-affetti-da-covid-19/ 2021-10-05T06:54:08+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/10/05/estensione-del-periodo-di-validita-di-comirnaty-flaconcino-chiuso/ 2021-10-05T06:58:51+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/10/05/nuove-informazioni-di-sicurezza-per-gli-operatori-sanitari-su-vaccini-covid-19-janssen-e-vaxzevria/ 2021-10-05T07:03:34+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/05/I_coronavirus_vaccine.jpg https://www.farmacovigilanzasardegna.it/2021/10/05/comirnaty-e-spikevax-raccomandazioni-ema-su-dosi-aggiuntive-e-richiami/ 2021-10-05T07:06:02+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/10/08/sito-produttivo-aggiuntivo-per-il-vaccino-covid-19-vaccine-janssen/ 2021-10-08T06:55:07+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/09/29/aifa-rende-disponibili-i-medicinali-anakinra-baricitinib-e-sarilumab-per-il-trattamento-del-covid-19/ 2021-10-12T06:35:53+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/09/28/ema-valuta-i-dati-sulla-dose-di-richiamo-del-vaccino-anti-covid-19-spikevax/ 2021-10-12T06:36:28+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/10/12/lema-riceve-la-domanda-di-aic-per-ronapreve-casirivimab-imdevimab-per-il-trattamento-e-la-prevenzione-di-covid-19/ 2021-10-12T07:20:55+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/10/13/nono-rapporto-aifa-sulla-sorveglianza-dei-vaccini-covid-19/ 2021-10-13T07:06:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/04/primula.png https://www.farmacovigilanzasardegna.it/2021/10/13/assl-sassari-corso-ecm-farmacovigilanza-e-vaccinovigilanza-sicurezza-dei-vaccini-anti-covid-19/ 2021-10-13T07:45:34+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/05/logo_CRFVSardegna.jpg https://www.farmacovigilanzasardegna.it/2021/10/13/nota-informativa-importante-su-vaxzevria-covid-19-vaccine-astrazeneca-2/ 2021-10-13T08:06:07+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/10/13/nota-informativa-importante-su-covid-19-vaccine-janssen/ 2021-10-13T08:20:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/10/15/ema-avvia-la-rolling-review-di-evusheld-tixagevimab-e-cilgavimab/ 2021-10-15T07:23:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/10/15/chiarimenti-sulla-tempistica-di-presentazione-di-una-variazione-di-modifica-stampati-a-seguito-di-una-raccomandazione-del-prac/ 2021-10-15T07:25:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/10/19/ema-avvia-la-valutazione-delluso-di-comirnaty-vaccino-covid-19-in-bambini-di-eta-compresa-tra-5-e-11-anni/ 2021-10-19T06:49:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/10/19/un-ampio-studio-di-sorveglianza-postmarketing-dei-farmaci-biologici-per-malattie-infiammatorie-immunomediate-in-italia-il-progetto-valore/ 2021-10-19T11:49:00+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/10/medicine.png https://www.farmacovigilanzasardegna.it/2021/10/25/covid-19-ema-avvia-la-rolling-review-di-molnupiravir/ 2021-10-25T13:57:23+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/10/27/spikevax-raccomandazione-ema-sulla-dose-di-richiamo/ 2021-11-02T07:13:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/11/02/parere-della-commissione-tecnico-scientifica-di-aifa-sulla-somministrazione-di-una-dose-booster-del-vaccino-spikevax-contro-il-covid-19/ 2021-11-02T08:08:08+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/11/02/nota-informativa-importante-su-forxiga-dapagliflozin/ 2021-11-02T08:13:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/11/02/comunicazione-ema-su-imbruvica/ 2021-11-02T08:16:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/11/03/interrotta-la-rolling-review-degli-anticorpi-bamlanivimab-ed-etesevimab-per-il-trattamento-di-covid-19-dopo-il-ritiro-da-parte-di-lilly/ 2021-11-03T08:15:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/11/04/parere-della-commissione-tecnico-scientifica-di-aifa-sulla-somministrazione-di-una-dose-booster-del-vaccino-janssen-contro-il-covid-19/ 2021-11-04T07:28:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/11/05/nota-informativa-importante-su-beovu-brolucizumab/ 2021-11-05T07:38:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/11/09/covid-19-aggiornamento-ema-hma-su-molnupiravir/ 2021-11-09T07:20:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/11/10/ema-avvia-la-valutazione-delluso-del-vaccino-covid-19-spikevax-in-bambini-di-eta-compresa-tra-6-e-11-anni/ 2021-11-10T12:20:42+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/11/12/nota-informativa-importante-su-visudyne-verteporfin/ 2021-11-12T09:37:23+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/11/21/ema-avvia-la-revisione-di-paxlovid-per-il-trattamento-di-pazienti-con-covid-19/ 2021-11-21T11:55:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/11/21/lema-riceve-la-domanda-di-autorizzazione-allimmissione-in-commercio-per-xevudy-sotrovimab-per-il-trattamento-di-pazienti-con-covid-19/ 2021-11-21T11:56:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/11/23/ema-valuta-i-dati-sulla-dose-di-richiamo-di-covid-19-vaccine-janssen/ 2021-11-23T12:05:42+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/11/23/ema-formula-un-parere-sulluso-di-lagevrio-molnupiravir-per-il-trattamento-di-covid-19/ 2021-11-23T12:09:47+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/11/24/il-centro-di-monitoraggio-sulla-sicurezza-dei-farmaci-di-uppsala-pubblica-un-numero-del-suo-bollettino-sulla-sicurezza-dei-vaccini/ 2021-11-24T08:19:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/08/upp.jpg https://www.farmacovigilanzasardegna.it/2021/11/24/lema-riceve-la-domanda-di-autorizzazione-allimmissione-in-commercio-per-lagevrio-molnupiravir-per-il-trattamento-dei-pazienti-con-covid-19/ 2021-11-24T12:36:15+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/11/25/comirnaty-vaccino-anti-covid-19-ema-raccomanda-lapprovazione-per-i-bambini-di-eta-compresa-tra-5-e-11-anni/ 2021-11-25T16:45:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/12/02/aifa-approva-il-vaccino-comirnaty-per-la-fascia-di-eta-5-11-anni/ 2021-12-02T07:33:53+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/12/03/ema-avvia-la-rolling-review-del-vaccino-anti-covid-19-di-valneva-vla2001/ 2021-12-03T07:22:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/12/05/aggiornamento-sul-rischio-di-miocardite-e-pericardite-con-vaccini-mrna/ 2021-12-05T16:09:21+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/04/primula.png https://www.farmacovigilanzasardegna.it/2021/12/09/ema-raccomanda-lapprovazione-delluso-di-roactemra-in-adulti-con-covid-19-grave/ 2021-12-09T07:27:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/12/09/nota-informativa-importante-su-lymphoseek-tilmanocept/ 2021-12-09T07:30:52+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/12/12/atti-del-xxx-seminario-nazionale-dellistituto-superiore-di-sanita-sindrome-dress-confronto-tra-i-dati-italiani-ed-europei-di-farmacovigilanza/ 2021-12-12T17:06:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/12/Logo-ISS-1.jpg https://www.farmacovigilanzasardegna.it/2021/12/12/atti-del-xxx-seminario-nazionale-dellistituto-superiore-di-sanita-vaccini-anti-covid-e-alterazioni-del-ciclo-mestruale/ 2021-12-12T17:15:34+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/12/Logo-ISS-1.jpg https://www.farmacovigilanzasardegna.it/2021/12/14/aggiornamento-procedura-operativa-aifa-per-i-responsabili-locali-di-farmacovigilanza-rlfv/ 2021-12-14T07:58:45+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2021/12/16/covid-19-vaccine-janssen-raccomandazione-ema-sulla-dose-di-richiamo/ 2021-12-16T07:21:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/12/16/il-tofacitinib-e-associato-ad-una-maggiore-incidenza-di-eventi-cardiovascolari-e-neoplasie/ 2021-12-16T11:52:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/12/joint.png https://www.farmacovigilanzasardegna.it/2021/12/16/riesame-ema-dei-dati-sullefficacia-di-lagevrio-molnupiravir-per-il-trattamento-di-covid-19/ 2021-12-16T14:06:33+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/12/17/ema-raccomanda-lapprovazione-di-kineret-in-adulti-con-covid-19/ 2021-12-17T12:01:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/12/17/ema-formula-un-parere-sulluso-di-paxlovid-pf-07321332-e-ritonavir-per-il-trattamento-di-covid-19/ 2021-12-17T12:06:53+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/12/17/covid-19-ema-raccomanda-lautorizzazione-dellanticorpo-xevudy/ 2021-12-17T12:08:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2021/12/21/report-2021-delle-attivita-del-centro-regionale-di-farmacovigilanza-della-sardegna/ 2021-12-21T12:43:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/05/logo_CRFVSardegna.jpg https://www.farmacovigilanzasardegna.it/2021/12/23/aifa-approva-il-vaccino-nuvaxovid-novavax/ 2021-12-23T07:26:47+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/04/primula.png https://www.farmacovigilanzasardegna.it/2022/01/04/disponibilita-di-molnupiravir-e-remdesivir-nel-trattamento-dei-pazienti-non-ospedalizzati-per-covid-19-e-ad-alto-rischio-di-malattia-grave/ 2022-01-04T16:13:18+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/01/07/aifa-approva-la-dose-booster-con-il-vaccino-comirnaty-per-la-fascia-di-eta-12-15-anni/ 2022-01-07T08:16:51+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/04/primula.png https://www.farmacovigilanzasardegna.it/2022/01/11/ema-riceve-la-domanda-di-aic-subordinata-a-condizioni-per-paxlovid-per-il-trattamento-di-pazienti-con-covid-19/ 2022-01-11T09:27:18+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/01/14/aifa-non-esistono-antibiotici-efficaci-per-il-covid-19/ 2022-01-14T09:34:38+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/01/15/avviata-revisione-dei-medicinali-a-base-di-terlipressina/ 2022-01-15T16:20:48+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/01/19/nota-informativa-importante-su-nulojix-belatacept/ 2022-01-19T07:20:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/01/19/highlights-della-riunione-del-comitato-per-la-valutazione-dei-rischi-in-farmacovigilanza-prac-10-13-gennaio-2022/ 2022-01-19T07:25:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/01/19/avviata-revisione-dei-medicinali-a-base-di-terlipressina-2/ 2022-01-19T07:42:07+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/01/21/dati-preliminari-indicano-che-i-vaccini-anti-covid-19-rimangono-efficaci-contro-la-malattia-grave-e-i-ricoveri-dovuti-alla-variante-omicron/ 2022-01-21T07:37:30+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/01/21/covid-19-recenti-dati-di-sicurezza-rassicurano-sulluso-dei-vaccini-a-mrna-in-gravidanza/ 2022-01-21T07:44:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/01/26/aumentato-rischio-di-herpes-zoster-in-pazienti-con-artrite-reumatoide-in-trattamento-con-upadacitinib/ 2022-01-26T12:20:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/12/joint.png https://www.farmacovigilanzasardegna.it/2022/01/27/aifa-la-nota-100-amplia-la-possibilita-di-prescrizione-dei-farmaci-antidiabetici-ai-medici-di-medicina-generale-e-agli-specialisti/ 2022-01-27T07:18:57+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/01/27/nota-informativa-importante-su-miturox-mitomicina-40-mg/ 2022-01-27T10:39:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/01/28/covid-19-ema-raccomanda-lautorizzazione-allimmissione-in-commercio-subordinata-a-condizioni-per-paxlovid/ 2022-01-28T07:26:53+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/02/01/aifa-definisce-le-modalita-di-utilizzo-di-paxlovid-presto-disponibile-in-italia/ 2022-02-01T07:33:21+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/02/01/nota-informativa-importante-su-medicinali-a-base-di-irinotecan/ 2022-02-01T07:36:00+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/02/02/il-tramadolo-utilizzato-per-gestire-il-dolore-cronico-e-associato-ad-un-rischio-di-mortalita-piu-elevato-rispetto-alla-codeina/ 2022-02-02T11:08:07+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/drug-4938120_1920.jpg https://www.farmacovigilanzasardegna.it/2022/02/07/nota-informativa-importante-su-medicinali-a-base-di-donepezil/ 2022-02-07T11:22:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/02/09/ema-valuta-i-dati-sulla-dose-di-richiamo-del-vaccino-anti-covid-19-comirnaty-negli-adolescenti/ 2022-02-09T12:50:44+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/02/09/nota-informativa-importante-su-sarilumab-kevzara/ 2022-02-09T12:56:00+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/02/09/aifa-presenta-il-rapporto-annuale-sulla-sicurezza-dei-vaccini-anti-covid-19-2/ 2022-02-10T08:35:05+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/02/R_Vaccini_COVID-19_09_02_2022.jpg https://www.farmacovigilanzasardegna.it/2022/02/10/il-crfv-sardegna-pubblica-il-bollettino-semestrale-di-farmacovigilanza/ 2022-02-10T08:35:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/close-up-picture-docter-s-hands-holding-hypodermic-syringe-scaled.jpg https://www.farmacovigilanzasardegna.it/2022/02/15/nota-informativa-importante-su-mavenclad-cladribina/ 2022-02-15T07:35:55+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/02/15/lema-avvia-la-revisione-dei-dati-di-sicurezza-degli-inibitori-della-janus-chinasi-per-i-disturbi-infiammatori/ 2022-02-15T07:44:59+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/02/15/estratto-dagli-highlights-della-riunione-del-prac-del-7-10-febbraio-2022/ 2022-02-15T07:47:37+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/02/15/il-prac-raccomanda-la-sospensione-dal-mercato-delle-soluzioni-di-amido-idrossietilico-per-infusione/ 2022-02-15T07:49:29+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/02/22/nota-informativa-importante-su-xagrid-anagrelide-cloridrato/ 2022-02-22T12:25:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/02/28/raccomandata-la-sospensione-dal-mercato-delle-soluzioni-a-base-di-amido-idrossietilico-per-infusione/ 2022-02-28T12:34:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/02/28/vaccino-nuvaxovid-contro-covid-19/ 2022-02-28T12:44:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/04/primula.png https://www.farmacovigilanzasardegna.it/2022/03/03/diventa-applicabile-il-regolamento-relativo-allampliamento-del-mandato-dellema/ 2022-03-03T12:36:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/03/08/nota-informativa-importante-su-infliximab-remicade-flixabi-inflectra-remsima-e-zessly/ 2022-03-08T12:46:23+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/03/12/aifa-pubblica-il-rapporto-antibiotici-2020/ 2022-03-12T10:13:05+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/03/Immagine_OsMed-anibiotici-2020.jpg https://www.farmacovigilanzasardegna.it/2022/03/14/highlights-della-riunione-del-comitato-per-la-valutazione-dei-rischi-in-farmacovigilanza-prac/ 2022-03-14T11:31:38+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/03/16/aifa-pubblica-il-rapporto-vaccini-2020/ 2022-03-16T11:14:49+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2020/09/5440812_1619_vaccini.jpg https://www.farmacovigilanzasardegna.it/2022/03/16/nota-informativa-importante-su-valcyte/ 2022-03-16T11:17:06+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/03/16/associazione-tra-polisolfato-di-pentosano-sodico-e-disturbi-della-retina/ 2022-03-16T13:00:30+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/08/I_terapia.jpg https://www.farmacovigilanzasardegna.it/2022/03/23/campagna-sulluso-consapevole-degli-antibiotici-2022/ 2022-03-23T10:14:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/03/Banner_300x250.jpg https://www.farmacovigilanzasardegna.it/2022/03/23/associazione-della-tipologia-di-anticoagulante-orale-con-gli-esiti-clinici-avversi-in-pazienti-che-continuano-la-terapia-anticoagulante-oltre-i-90-giorni-dopo-il-ricovero-per-tromboembolia-venosa/ 2022-03-23T10:58:31+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/coagulazione1.jpg https://www.farmacovigilanzasardegna.it/2022/03/24/horizon-scanning-scenario-dei-medicinali-in-arrivo-aifa-pubblica-il-rapporto-2022/ 2022-03-24T16:43:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/04/01/aifa-necessari-ulteriori-approfondimenti-su-secondo-booster-vaccini-covid-19/ 2022-04-01T06:50:50+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/04/01/ema-raccomanda-lautorizzazione-di-evusheld-medicinale-anti-covid-19/ 2022-04-01T06:52:33+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/04/13/estratto-dagli-highlights-della-riunione-del-comitato-per-la-valutazione-dei-rischi-in-farmacovigilanza-prac-del-4-7-aprile-2022/ 2022-04-13T08:22:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/04/20/undicesimo-rapporto-aifa-sulla-sorveglianza-dei-vaccini-anti-covid-19/ 2022-04-20T07:07:47+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/04/19/concentrazioni-di-farmaci-antiepilettici-durante-la-gravidanza-risultati-dello-studio-maternal-outcomes-and-neurodevelopmental-effects-of-antiepileptic-drugs-monead/ 2022-04-20T07:12:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/07/pd.png https://www.farmacovigilanzasardegna.it/2022/05/03/lema-avvia-la-revisione-del-medicinale-antitumorale-rubraca/ 2022-05-03T11:35:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/05/03/nota-informativa-importante-su-natpar-ormone-paratiroideo/ 2022-05-03T13:32:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/05/05/aggiornamento-sulla-pratica-clinica-della-revoca-della-prescrizione-di-inibitori-della-pompa-protonica-revisione-di-esperti/ 2022-05-05T11:14:06+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/drug-4938120_1920.jpg https://www.farmacovigilanzasardegna.it/2022/05/06/nota-informativa-importante-su-rucaparib-rubraca/ 2022-05-06T06:54:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/05/11/potenziale-nefrotossico-di-167-farmaci-in-pazienti-adulti-in-condizioni-critiche/ 2022-05-11T11:57:05+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/05/asdf.png https://www.farmacovigilanzasardegna.it/2022/05/12/profilo-di-sicurezza-di-erenumab-galcanezumab-e-fremanezumab-in-gravidanza-e-allattamento-analisi-del-database-di-farmacovigilanza-delloms/ 2022-05-12T14:15:44+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/05/mal-di-testa-emicrania.jpg https://www.farmacovigilanzasardegna.it/2022/05/13/report-annuale-di-attivita-del-centro-regionale-di-farmacovigilanza-della-sardegna/ 2022-05-13T09:09:58+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/copertina_SGiovanniDioFront.jpg https://www.farmacovigilanzasardegna.it/2022/05/17/nota-informativa-importante-su-bactrimel/ 2022-05-17T14:07:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/06/03/nota-informativa-importante-su-lymphoseek-tilmanocept-2/ 2022-06-03T09:02:05+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/06/03/aggiornamento-elenco-farmaci-innovativi-maggio-2022/ 2022-06-03T09:06:30+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/10/medicine.png https://www.farmacovigilanzasardegna.it/2022/06/03/nota-informativa-importante-su-soluzioni-per-infusione-contenenti-amido-idrossietilico-hes/ 2022-06-03T09:08:07+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/06/03/nuova-rete-nazionale-di-farmacovigilanza-aifa/ 2022-06-07T10:41:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/06/07/avvio-della-nuova-rete-nazionale-di-farmacovigilanza/ 2022-06-07T10:42:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/06/RNF_600x400_Up.jpg https://www.farmacovigilanzasardegna.it/2022/06/09/lema-adotta-la-prima-lista-di-farmaci-critici-per-il-covid-19/ 2022-06-09T11:17:04+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/10/antibiotic-resistant.png https://www.farmacovigilanzasardegna.it/2022/06/10/nota-informativa-importante-su-ocaliva-acido-obeticolico/ 2022-06-10T10:35:08+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/06/13/ema-raccomanda-il-ritiro-dellautorizzazione-allimmissione-in-commercio-per-i-medicinali-a-base-di-amfepramone/ 2022-06-13T12:32:30+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/06/13/nota-informativa-importante-su-defitelio-defibrotide/ 2022-06-13T12:34:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/06/13/aggiornamenti-di-sicurezza-da-parte-del-comitato-per-la-valutazione-dei-rischi-in-farmacovigilanza-prac-del-7-10-giugno-2022/ 2022-06-13T12:36:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/06/13/congresso-international-society-of-pharmacovigilance-isop-2022-a-verona-dal-20-al-23-settembre-2022/ 2022-06-13T12:47:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/06/20110720_Verona_3078-scaled.jpg https://www.farmacovigilanzasardegna.it/2022/06/16/nota-informativa-importante-su-dexmedetomidina/ 2022-06-16T11:52:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/06/16/avvio-della-rolling-review-per-laggiornamento-del-vaccino-anti-covid-19-comirnaty/ 2022-06-16T12:01:02+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/06/20/rischio-cardiovascolare-associato-alluso-di-remdesivir-in-pazienti-affetti-da-covid-19/ 2022-06-20T15:31:02+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/10/antibiotic-resistant.png https://www.farmacovigilanzasardegna.it/2022/06/20/uso-prolungato-di-inibitori-della-pompa-protonica-e-rischio-di-diabete-di-tipo-2/ 2022-06-20T16:03:15+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/09/pillolePlacebo-e1601024201590.jpg https://www.farmacovigilanzasardegna.it/2022/06/21/avvio-della-rolling-review-per-laggiornamento-del-vaccino-anti-covid-19-spikevax/ 2022-06-21T13:20:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/06/21/miglioramento-delle-conoscenze-e-gestione-degli-eventi-avversi-immuno-correlati-nellimmunoterapia-delle-malattie-tumorali/ 2022-06-21T13:24:50+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/11/drop-pink-chemicals-into-beaker-scaled.jpg https://www.farmacovigilanzasardegna.it/2022/06/21/sicurezza-della-terapia-di-deplezione-degli-eosinofili-per-lasma-grave-eosinofilico-focus-su-benralizumab/ 2022-06-21T13:29:20+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/03/lungs.png https://www.farmacovigilanzasardegna.it/2022/06/27/ema-raccomanda-lautorizzazione-nellue-del-vaccino-anti-covid-19-valneva/ 2022-06-27T06:59:55+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/06/27/ema-raccomanda-lautorizzazione-del-vaccino-anti-covid-19-nuvaxovid-negli-adolescenti-di-eta-compresa-tra-12-e-17-anni/ 2022-06-27T07:09:38+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/06/27/nuove-schede-di-segnalazione-delle-reazioni-avverse-a-farmaci-e-vaccini/ 2022-06-27T07:18:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/06/RNF_600x400_Up.jpg https://www.farmacovigilanzasardegna.it/2022/06/27/segnalare-online-una-sospetta-reazione-avversa-a-farmaco-o-vaccino-tramite-la-nuova-rete-nazionale-di-farmacovigilanza/ 2022-06-27T07:23:20+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/06/RNF_600x400_Up.jpg https://www.farmacovigilanzasardegna.it/2022/06/27/al-via-la-nuova-rete-nazionale-di-farmacovigilanza-rnf/ 2022-06-27T07:27:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/06/RNF_600x400_Up.jpg https://www.farmacovigilanzasardegna.it/2022/06/27/nota-informativa-importante-su-plasmagrade-plasma-umano-congelato/ 2022-06-27T14:45:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/06/28/eventi-avversi-legati-agli-integratori-alimentari-a-base-di-erbe-e-farmaci-da-banco-contenenti-lassativi-un-aggiornamento-a-10-anni-dai-sistemi-italiani-di-fitovigilanza-e-farmacovigilanza/ 2022-06-28T08:04:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/04/inegratori-alimentari-funzionano-scaled.jpg https://www.farmacovigilanzasardegna.it/2022/06/30/reazioni-avverse-a-olanzapina-clozapina-e-loxapina-nei-bambini-e-nei-giovani-una-revisione-farmacogenetica-sistematica/ 2022-06-30T10:59:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/tablets-3442768_960_720.jpg https://www.farmacovigilanzasardegna.it/2022/07/04/il-comitato-per-i-medicinali-per-uso-umano-chmp-dellema-ha-raccomandato-lapprovazione-di-nove-nuovi-farmaci-nella-riunione-di-giugno-2022/ 2022-07-04T08:53:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/07/05/vaiolo-delle-scimmie-lema-avvia-la-revisione-di-imvanex/ 2022-07-05T13:28:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/07/05/rischio-comparativo-di-malattia-di-alzheimer-tra-pazienti-affetti-da-artrite-reumatoide-in-terapia-con-farmaci-antireumatici-a-bersaglio-molecolare-modificanti-la-malattia/ 2022-07-05T14:30:57+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/knee-1406964_1920.jpg https://www.farmacovigilanzasardegna.it/2022/07/06/sicurezza-ed-efficacia-a-lungo-termine-di-ozanimod-nella-sclerosi-multipla-recidiveante-remittente-fino-a-5-anni-di-follow-up-nel-trial-di-estensione-in-aperto-daybreak/ 2022-07-06T08:02:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/05/mal-di-testa-emicrania.jpg https://www.farmacovigilanzasardegna.it/2022/07/06/rischio-di-psoriasi-dopo-esposizione-ai-beta-bloccanti/ 2022-07-06T09:45:59+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2020/02/psoriasiday-preview-default.jpg https://www.farmacovigilanzasardegna.it/2022/07/08/le-agenzie-regolatorie-mondiali-concordano-sui-principi-chiave-delladattamento-dei-vaccini-per-affrontare-le-varianti-virali/ 2022-07-08T08:05:50+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/07/08/medicinali-contenenti-nomegestrolo-o-clormadinone-il-prac-raccomanda-nuove-misure-per-minimizzare-il-rischio-di-meningioma/ 2022-07-08T10:54:58+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/07/11/lecdc-e-lema-aggiornano-le-raccomandazioni-sulle-dosi-di-richiamo-aggiuntive-dei-vaccini-mrna-covid-19/ 2022-07-11T11:43:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/07/12/vaccini-anti-covid-19-estensione-della-platea-dei-destinatari-della-seconda-dose-di-richiamo/ 2022-07-12T11:09:50+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/07/maxresdefault.jpg https://www.farmacovigilanzasardegna.it/2022/07/19/reazioni-di-ipersensibilita-ai-farmaci-non-mediate-dalle-ige/ 2022-07-19T08:42:23+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/02/hives.png https://www.farmacovigilanzasardegna.it/2022/07/19/sicurezza-della-fexofenadina-e-di-altri-antistaminici-orali-di-seconda-generazione/ 2022-07-19T15:08:50+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/02/sneeze.png https://www.farmacovigilanzasardegna.it/2022/07/19/uveite-indotta-da-brentuximab-vedotin/ 2022-07-19T16:13:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/eye-369557_1920.jpg https://www.farmacovigilanzasardegna.it/2022/07/20/incidenza-patogenesi-e-gestione-della-nefrotossicita-indotta-da-inibitori-di-pompa-protonica/ 2022-07-20T08:29:15+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/05/asdf.png https://www.farmacovigilanzasardegna.it/2022/07/20/pancreas-e-reazioni-avverse-ai-farmaci-una-revisione-della-letteratura%ef%bf%bc/ 2022-07-20T10:15:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/07/Pancreas-scaled.jpeg https://www.farmacovigilanzasardegna.it/2022/07/22/incidenza-di-insufficienza-renale-acuta-nei-pazienti-che-utilizzano-levetiracetam-rispetto-ad-altri-farmaci-antiepilettici/ 2022-07-22T08:51:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/07/pd.png https://www.farmacovigilanzasardegna.it/2022/07/25/nota-informativa-importante-su-mitomicina-medac/ 2022-07-25T08:10:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/07/25/comunicazione-aifa-su-medicinale-rasilez-hct-aliskiren-idroclorotiazide/ 2022-07-25T08:11:15+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/07/26/lema-raccomanda-lapprovazione-di-imvanex-per-la-prevenzione-del-vaiolo-delle-scimmie/ 2022-07-26T06:39:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/07/27/raccolta-di-dati-sugli-eventi-avversi-correlati-ai-medicinali-unindagine-tra-i-registri-del-database-encepp/ 2022-07-27T07:25:58+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2019/01/logo_DrugSafety.jpg https://www.farmacovigilanzasardegna.it/2022/07/26/lema-raccomanda-di-limitare-luso-del-medicinale-antitumorale-rubraca/ 2022-07-27T09:34:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/07/27/dodicesimo-rapporto-aifa-sulla-sorveglianza-dei-vaccini-anti-covid-19/ 2022-07-27T11:56:14+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/07/R_Vaccini_Covid-19.png https://www.farmacovigilanzasardegna.it/2022/07/29/biomarcatori-renali-ed-eventi-avversi-renali-maggiori-in-pazienti-in-condizioni-critiche/ 2022-07-29T06:46:34+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/05/asdf.png https://www.farmacovigilanzasardegna.it/2022/07/29/analisi-delle-segnalazioni-di-reazioni-avverse-ai-farmaci-e-agli-integratori-a-base-di-erbe-ricevute-dal-centro-nazionale-di-farmacovigilanza-lareb-nei-paesi-bassi/ 2022-07-29T07:00:15+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/04/inegratori-alimentari-funzionano-scaled.jpg https://www.farmacovigilanzasardegna.it/2022/07/29/terapia-con-anti-tnf-alfa-e-ipoglicemia-unanalisi-di-farmacovigilanza-real-word/ 2022-07-29T08:08:32+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/knee-1406964_1920.jpg https://www.farmacovigilanzasardegna.it/2022/07/29/sorveglianza-post-marketing-delle-terapie-con-cellule-car-t-analisi-del-database-del-sistema-di-segnalazione-degli-eventi-avversi-della-fda-faers/ 2022-07-29T08:15:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/11/drop-pink-chemicals-into-beaker-scaled.jpg https://www.farmacovigilanzasardegna.it/2022/07/29/luso-dei-farmaci-in-italia-rapporto-osmed-2021/ 2022-07-29T09:37:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/07/29/il-crfv-sardegna-pubblica-il-bollettino-semestrale-di-farmacovigilanza-con-un-focus-sugli-anticorpi-monoclonali/ 2022-07-29T11:41:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/07/I_anticorpi_monoclonali_02.jpeg https://www.farmacovigilanzasardegna.it/2022/08/17/i-dati-del-rapporto-osmed-2021-in-modalita-interattiva/ 2022-08-17T08:25:48+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/08/17/risposta-dellema-allemergenza-sanitaria-pubblica-del-vaiolo-delle-scimmie/ 2022-08-17T08:27:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/08/17/ema-inizia-la-valutazione-dei-dati-sulluso-di-sabizabulina-per-il-trattamento-di-covid-19/ 2022-08-17T08:28:22+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/08/17/nota-informativa-importante-su-caprelsa-vandetanib/ 2022-08-17T08:31:41+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/08/17/nota-informativa-importante-su-visudyne-verteporfin-2/ 2022-08-17T08:33:15+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/08/17/nota-informativa-importante-su-rubraca-rucaparib/ 2022-08-17T08:34:55+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/08/17/aifa-autorizza-lutilizzo-terapeutico-del-monoclonale-evusheld-per-il-trattamento-precoce-del-covid-19-in-soggetti-a-rischio-di-progressione/ 2022-08-17T08:37:04+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/08/22/confronto-delleffetto-di-15-antidepressivi-per-valutare-la-comparsa-della-sindrome-da-sospensione-uno-studio-real-world-utilizzando-il-database-who-di-farmacovigilanza/ 2022-08-22T11:38:22+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/hand-3632914_640.jpg https://www.farmacovigilanzasardegna.it/2022/08/22/la-task-force-dellema-per-le-emergenze-fornisce-un-parere-sulluso-intradermico-del-vaccino-imvanex-jynneos-contro-il-vaiolo-delle-scimmie/ 2022-08-22T11:40:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/08/22/lagenzia-europea-per-i-medicinali-ha-avviato-la-procedura-di-approvazione-subordinata-a-condizioni-del-vaccino-anti-covid-19-skycovion/ 2022-08-22T11:42:44+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/08/23/unanalisi-di-sproporzionalita-delle-interazioni-farmaco-farmaco-tra-tizanidina-e-inibitori-del-cyp1a2e-inibitori-del-cyp1a2-dal-sistema-di-segnalazione-degli-eventi-avversi-della-fda/ 2022-08-23T07:52:52+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/07/pd.png https://www.farmacovigilanzasardegna.it/2022/08/26/sicurezza-comparativa-dei-vaccini-covid-19-a-mrna-con-i-vaccini-antinfluenzali-unanalisi-di-farmacovigilanza-utilizzando-database-internazionale-delloms/ 2022-08-26T09:57:41+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/close-up-picture-docter-s-hands-holding-hypodermic-syringe-scaled.jpg https://www.farmacovigilanzasardegna.it/2022/08/26/rischio-di-miocardite-in-seguito-a-dosi-sequenziali-divaccino-covid-19-e-infezione-da-sars-cov-2per-eta-e-sesso/ 2022-08-26T10:17:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/vaccine.png https://www.farmacovigilanzasardegna.it/2022/09/01/farmaci-biosimilari-in-italia-report-aifa-aggiornati-ad-aprile-2022/ 2022-09-01T10:28:48+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/05/I_Biosimilari.jpg https://www.farmacovigilanzasardegna.it/2022/09/01/raccomandata-lapprovazione-del-primo-vaccino-di-richiamo-covid-19-adattato-nellue/ 2022-09-01T13:16:14+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/05/I_coronavirus_vaccine.jpg https://www.farmacovigilanzasardegna.it/2022/09/02/nuove-misure-per-minimizzare-il-rischio-di-meningioma-per-i-medicinali-contenenti-nomegestrolo-o-clormadinone/ 2022-09-02T11:44:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/09/06/avviata-la-revisione-dei-medicinali-a-base-di-folcodina/ 2022-09-06T13:17:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/09/06/aifa-approva-dose-booster-con-vaccini-bivalenti-comirnaty-e-spikevax/ 2022-09-06T13:33:53+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/09/06/il-prac-avvia-la-revisione-sulluso-del-topiramato-in-gravidanza-e-nelle-donne-in-eta-fertile/ 2022-09-06T13:34:30+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/09/06/efficacia-clinica-e-sicurezza-degli-agenti-antivirali-prescritti-ai-pazienti-con-covid-19-non-ospedalizzati-una-review-sistematica-e-metanalisi-dei-trial-randomizzati-controllati/ 2022-09-06T15:07:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/vaccine.png https://www.farmacovigilanzasardegna.it/2022/09/07/gestione-terapeutica-del-danno-epatico-indotto-da-farmaci-idiosincratici-e-dellepatotossicita-da-paracetamolo-nella-popolazione-pediatrica-una-revisione-sistematica/ 2022-09-08T11:30:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/03/Gray1224.png https://www.farmacovigilanzasardegna.it/2022/09/13/covid-19-raccomandazioni-sulluso-dei-vaccini-adattati/ 2022-09-13T11:02:20+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/09/13/fans-per-uso-sistemico-richiesta-di-modifica-stampati-per-luso-in-gravidanza/ 2022-09-13T11:05:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/09/13/nota-informativa-importante-su-nulojix-belatacept-2/ 2022-09-13T11:07:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/09/13/aifa-vaccini-influenzali-per-la-stagione-2022-2023/ 2022-09-13T11:10:48+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/close-up-picture-docter-s-hands-holding-hypodermic-syringe-scaled.jpg https://www.farmacovigilanzasardegna.it/2022/09/13/lema-raccomanda-lapprovazione-del-vaccino-adattato-contro-le-varianti-di-omicron-ba-4-e-ba-5-e-il-ceppo-originario-di-sars-cov-2/ 2022-09-13T11:15:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/09/14/previsione-quantitativa-della-probabilita-di-eventi-avversi-dovuti-a-interazioni-farmacocinetiche/ 2022-09-14T11:26:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/tablets-3442768_960_720.jpg https://www.farmacovigilanzasardegna.it/2022/09/20/aifa-autorizza-il-vaccino-bivalente-comirnaty-original-per-le-varianti-omicron-ba-4-5/ 2022-09-20T11:30:55+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/09/20/efficacia-e-sicurezza-degli-anticoagulanti-nei-pazienti-con-fibrillazione-atriale-e-storia-di-cadute-o-rischio-di-cadute-una-revisione-sistematica-e-una-meta-analisi-multilivello/ 2022-09-20T11:38:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/coagulazione1.jpg https://www.farmacovigilanzasardegna.it/2022/09/20/sorveglianza-della-sicurezza-dei-farmaci-in-eta-pediatrica-unanalisi-decennale-dei-dati-di-segnalazione-delle-reazioni-avverse-ai-farmaci-in-calabria-italia/ 2022-09-20T11:47:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/02/hives.png https://www.farmacovigilanzasardegna.it/2022/09/27/synchron-research-service-il-riesame-conferma-la-sospensione-di-medicinali-a-causa-di-irregolarita-negli-studi/ 2022-09-27T08:20:59+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/09/27/nota-informativa-importante-su-nulojix-belatacept-3/ 2022-09-27T08:22:00+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/09/27/lema-raccomanda-lautorizzazione-allimmissione-in-commercio-standard-per-i-vaccini-anti-covid-19-comirnaty-e-spikevax/ 2022-09-27T08:23:14+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/09/27/dichiarazione-ema-hma-sullintercambiabilita-dei-medicinali-biosimilari-nellue/ 2022-09-27T08:25:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/09/27/segnalazione-di-adr-da-cittadino-analisi-dei-dati-della-regione-sardegna/ 2022-09-27T10:07:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/09/isop.png https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/09/POSTER-ISOP-1_page-0001-scaled.jpg https://www.farmacovigilanzasardegna.it/2022/09/27/vaccini-covid-19-e-disturbi-mestruali-report-del-centro-regionale-sardo-di-farmacovigilanza/ 2022-09-27T10:20:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/09/isop.png https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/09/POSTER-E.-ISOP-2-scaled.jpg https://www.farmacovigilanzasardegna.it/2022/09/27/sicurezza-e-tollerabilita-del-dimetilfumarato-unanalisi-dei-dati-di-farmacovigilanza-nella-regione-sardegna/ 2022-09-27T10:41:37+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/09/isop.png https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/09/Poster-ISOP-3-scaled.jpg https://www.farmacovigilanzasardegna.it/2022/09/29/corso-ecm-farmacovigilanza-focus-sugli-anticorpi-monoclonali-federfarma-cagliari-10-e-24-novembre-2022/ 2022-09-29T08:42:31+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/05/logo_CRFVSardegna.jpg https://www.farmacovigilanzasardegna.it/2022/10/03/highlights-della-riunione-del-comitato-per-la-valutazione-dei-rischi-in-farmacovigilanza-prac-del-26-29-settembre-2022/ 2022-10-03T11:19:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/10/03/nuove-raccomandazioni-per-i-medicinali-a-base-di-terlipressina-nel-trattamento-della-sindrome-epatorenale/ 2022-10-03T11:24:05+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/10/05/nota-informativa-importante-su-natpar-ormone-paratiroideo-2/ 2022-10-05T06:39:50+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/10/07/sicurezza-di-apremilast-nei-pazienti-con-psoriasi-e-artrite-psoriasica-risultati-del-uk-clinical-practice-research-datalink/ 2022-10-07T09:24:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/12/joint.png https://www.farmacovigilanzasardegna.it/2022/10/13/medicinali-per-terapie-avanzate-atmps-progetto-pilota-ema-dedicato-a-istituti-di-ricerca-e-organizzazioni-non-profit/ 2022-10-13T07:40:34+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/10/13/vaccinazione-con-vaccino-pfizer-anti-covid-19-a-mrna-bnt162b2-e-vaccino-inattivato-coronavac-e-rischio-di-eventi-avversi-e-complicanze-diabetiche-acute-in-pazienti-con-diabete-mellito-di-tipo-2-u/ 2022-10-13T08:36:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/vaccine.png https://www.farmacovigilanzasardegna.it/2022/10/13/nota-informativa-importante-su-neorecormon-epoetina-beta/ 2022-10-13T08:38:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/10/19/intelligenza-artificiale-in-farmacovigilanza-e-sorveglianza-post-marketing-dei-farmaci/ 2022-10-19T08:50:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/12/analysis-4224502_1920.jpg https://www.farmacovigilanzasardegna.it/2022/10/21/ema-raccomanda-lapprovazione-dei-vaccini-anti-covid-19-comirnaty-e-spikevax-nei-bambini-a-partire-dai-6-mesi-di-eta/ 2022-10-21T07:32:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/10/21/ema-raccomanda-lapprovazione-del-secondo-vaccino-spikevax-adattato/ 2022-10-21T07:46:50+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2019/01/16/ema-comunicazioni-sulla-sicurezza-dei-farmaci-settembre-dicembre-2018/ 2022-10-24T10:38:23+00:00 https://www.farmacovigilanzasardegna.it/2017/08/31/aifa-le-principali-notizie-di-agosto-sulla-sicurezza-dei-farmaci-2/ 2022-10-24T10:42:50+00:00 https://www.farmacovigilanzasardegna.it/2022/11/02/highlights-della-riunione-del-comitato-per-la-valutazione-dei-rischi-in-farmacovigilanza-prac-del-24-27-ottobre-2022/ 2022-11-02T09:12:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/11/02/ema-conferma-la-raccomandazione-di-ritirare-le-autorizzazioni-allimmissione-in-commercio-per-i-medicinali-a-base-di-amfepramone/ 2022-11-02T09:15:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/11/02/lema-raccomanda-misure-per-minimizzare-il-rischio-di-gravi-effetti-collaterali-con-farmaci-inibitori-della-janus-chinasi-usati-per-disturbi-infiammatori-cronici/ 2022-11-02T09:17:07+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/11/03/nota-informativa-importante-su-imbruvica-ibrutinib/ 2022-11-03T12:55:07+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/11/04/tredicesimo-rapporto-aifa-sulla-sorveglianza-dei-vaccini-anti-covid-19/ 2022-11-04T08:48:32+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/close-up-picture-docter-s-hands-holding-hypodermic-syringe-scaled.jpg https://www.farmacovigilanzasardegna.it/2022/11/04/aumentare-la-consapevolezza-della-farmacovigilanza-sui-social-media/ 2022-11-04T11:40:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/11/MSW2022-WebBanner-Dates.png https://www.farmacovigilanzasardegna.it/2022/11/07/corso-ecm-farmacovigilanza-focus-sugli-anticorpi-monoclonali-aou-cagliari-14-novembre-e-1-dicembre-2022/ 2022-11-07T12:30:53+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/05/logo_CRFVSardegna.jpg https://www.farmacovigilanzasardegna.it/2022/11/08/nota-informativa-importante-su-xalkori-crizotinib/ 2022-11-08T16:05:30+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/11/22/le-iniziative-aifa-per-la-settimana-mondiale-dedicata-alluso-consapevole-degli-antibiotici/ 2022-11-22T08:10:23+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/03/Banner_300x250.jpg https://www.farmacovigilanzasardegna.it/2022/11/22/aifa-pubblica-le-raccomandazioni-sulla-terapia-mirata-delle-infezioni-resistenti/ 2022-11-22T08:16:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/03/Banner_300x250.jpg https://www.farmacovigilanzasardegna.it/2022/11/22/e-online-il-rapporto-sulle-attivita-di-aifa-nellemergenza-covid-19/ 2022-11-22T08:18:22+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/10/antibiotic-resistant.png https://www.farmacovigilanzasardegna.it/2022/11/22/nota-informativa-importante-su-medicinali-contenenti-clormadinone-acetato-o-nomegestrolo-acetato/ 2022-11-22T08:29:49+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/11/22/nota-informativa-importante-su-vaccini-bivalenti-spikevax/ 2022-11-22T08:32:41+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/11/22/ema-raccomanda-lapprovazione-del-vaccino-vidprevtyn-beta-come-richiamo-per-la-vaccinazione-covid-19/ 2022-11-22T08:33:53+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/11/22/chiarimenti-sulluso-appropriato-dei-farmaci-respiratori-con-somministrazione-tramite-erogatore/ 2022-11-22T08:35:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/11/23/antibiotico-resistenza-un-test-prodotto-da-aifa-valuta-quanto-ne-sai/ 2022-11-23T12:12:06+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/11/MSW2022-WebBanner-Dates.png https://www.farmacovigilanzasardegna.it/2022/11/25/attivazione-della-prescrizione-informatizzata-dei-farmaci-in-nota-100-da-parte-dei-medici-di-medicina-generale-tramite-il-sistema-ts/ 2022-11-25T15:38:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/12/02/comunicazione-di-sicurezza-su-finasteride-1-mg/ 2022-12-02T10:34:31+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/12/02/nota-informativa-importante-su-terlipressina/ 2022-12-02T10:35:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/12/02/aifa-lancia-una-app-per-informazioni-e-notifiche-sui-farmaci/ 2022-12-02T16:09:18+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/12/I_notizie.jpg https://www.farmacovigilanzasardegna.it/2022/12/09/lema-raccomanda-il-ritiro-dei-medicinali-a-base-di-folcodina-dal-mercato-dellue/ 2022-12-09T09:08:04+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2022/12/09/sindrome-da-astinenza-in-seguito-allinterruzione-di-28-antidepressivi-analisi-di-farmacovigilanza-di-31688-segnalazioni-dal-database-delle-reazioni-avverse-dellorganizzazione-mondia/ 2022-12-09T09:11:47+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/tablets-3442768_960_720.jpg https://www.farmacovigilanzasardegna.it/2022/12/15/nota-informativa-importante-su-caprelsa-vandetanib-2/ 2022-12-15T08:09:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/12/16/luso-dei-farmaci-in-italia-disponibile-la-versione-inglese-del-rapporto-osmed-2021/ 2022-12-16T09:00:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2022/12/21/sicurezza-dei-sali-di-litio-esperienza-della-lithium-clinic-di-cagliari/ 2022-12-21T07:57:53+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/12/Logo-ISS-1.jpg https://www.farmacovigilanzasardegna.it/2022/12/21/analisi-delle-reazioni-avverse-da-anticorpi-monoclonali-nella-regione-sardegna/ 2022-12-21T08:02:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/12/Logo-ISS-1.jpg https://www.farmacovigilanzasardegna.it/2022/12/21/andamento-delle-segnalazioni-di-reazioni-avverse-in-sardegna-durante-la-pandemia/ 2022-12-21T08:05:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/12/Logo-ISS-1.jpg https://www.farmacovigilanzasardegna.it/2022/12/21/reazioni-avverse-a-farmaci-calcio-omeostatici-analisi-dei-dati-della-sardegna/ 2022-12-21T08:08:59+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/12/Logo-ISS-1.jpg https://www.farmacovigilanzasardegna.it/2023/01/03/sperimentazioni-cliniche-decentrate-le-raccomandazioni-del-network-regolatorio-europeo-sui-medicinali/ 2023-01-03T08:33:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2023/01/03/aifa-pubblica-il-rapporto-vaccini-2021/ 2023-01-03T08:36:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/close-up-picture-docter-s-hands-holding-hypodermic-syringe-scaled.jpg https://www.farmacovigilanzasardegna.it/2023/01/03/procedura-operativa-po-aifa-per-i-rlfv-e-crfv/ 2023-01-03T08:40:38+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/01/12/tecartus-brexucbtagene-autoleucel-disponibile-il-report-tecnico-scientifico/ 2023-01-12T09:46:33+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/01/13/highlights-della-riunione-del-comitato-per-la-valutazione-dei-rischi-in-farmacovigilanza-prac-del-9-12-gennaio-2023/ 2023-01-13T15:32:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2023/01/16/olaparib-non-rimborsabile-per-il-carcinoma-del-pancreas/ 2023-01-16T12:30:29+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/07/pancreas.webp https://www.farmacovigilanzasardegna.it/2023/01/16/nota-informativa-importante-su-temporanea-carenza-di-insuman-rapid-insulina-umana/ 2023-01-16T12:33:58+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/01/18/studi-di-sicurezza-post-autorizzazione-sul-danno-epatico-acuto-e-sulle-gravi-complicanze-delle-infezioni-delle-vie-urinarie-in-pazienti-con-diabete-di-tipo-2-esposti-a-dapagliflozin-in-un-contesto-rea/ 2023-01-18T09:57:42+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/05/asdf.png https://www.farmacovigilanzasardegna.it/2023/01/18/valutazione-della-frequenza-dei-fenotipi-e-degli-esiti-del-danno-epatico-acuto-associato-allamoxicillina-clavulanato-in-14-milioni-di-pazienti-della-veterans-health-administration/ 2023-01-18T10:01:22+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/03/Gray1224.png https://www.farmacovigilanzasardegna.it/2023/01/20/il-crfv-sardegna-pubblica-il-bollettino-semestrale-di-farmacovigilanza-2/ 2023-01-20T10:38:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/01/Immagine1.jpg https://www.farmacovigilanzasardegna.it/2023/01/20/il-crfv-sardegna-pubblica-il-report-annuale-di-attivita-relativo-al-2022/ 2023-01-20T10:56:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/copertina_SGiovanniDioFront.jpg https://www.farmacovigilanzasardegna.it/2023/01/23/operativi-i-due-comitati-etici-nazionali-istituiti-presso-laifa/ 2023-01-23T12:58:06+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/01/23/presentate-le-piu-recenti-iniziative-per-ridurre-la-resistenza-agli-antibiotici-in-italia/ 2023-01-23T13:00:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/03/Banner_300x250.jpg https://www.farmacovigilanzasardegna.it/2023/01/25/nota-informativa-importante-su-temporanea-carenza-di-pazenir/ 2023-01-25T13:11:38+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/01/30/diabete-mellito-tipo-2-aggiornata-la-nota-100/ 2023-01-30T08:19:28+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/01/30/lema-conferma-le-misure-per-ridurre-al-minimo-il-rischio-di-gravi-effetti-collaterali-con-gli-inibitori-della-janus-chinasi-per-i-disturbi-infiammatori-cronici/ 2023-01-30T08:22:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2023/02/01/nota-informativa-importante-su-lymphoseek-tilmanocept-3/ 2023-02-01T07:40:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/02/03/un-pannello-farmacogenetico-di-12-geni-per-la-prevenzione-delle-reazioni-avverse-ai-farmaci-uno-studio-europeo-in-aperto-multicentrico-crossover-controllato/ 2023-02-03T12:00:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/09/pillolePlacebo-e1601024201590.jpg https://www.farmacovigilanzasardegna.it/2023/02/07/nota-informativa-importante-su-norditropin-nordiflex-somatropina-ormone-della-crescita-umano/ 2023-02-07T12:28:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/02/09/levotirsol-levotiroxina-sodica-modifica-temporanea-del-periodo-di-validita/ 2023-02-09T14:18:00+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/02/10/il-prac-avvia-la-revisione-della-sicurezza-dei-medicinali-contenenti-pseudoefedrina/ 2023-02-10T19:08:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2023/02/13/aifa-precisa-nessuna-problematica-urgente-di-sicurezza-per-i-farmaci-a-base-di-pseudoefedrina/ 2023-02-13T07:53:05+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/02/13/nota-informativa-importante-su-fasturtec-rasburicase/ 2023-02-13T12:04:57+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/02/14/nota-informativa-importante-su-adakveo-crizanlizumab/ 2023-02-14T15:32:42+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/02/21/nota-informativa-importante-su-zolgensma-onasemnogene-abeparvovec-2/ 2023-02-21T08:40:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/02/21/aggiornata-la-nota-aifa-96-prevenzione-e-trattamento-della-carenza-di-vitamina-d/ 2023-02-21T16:21:44+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/12/I_notizie.jpg https://www.farmacovigilanzasardegna.it/2023/03/02/nota-informativa-importante-su-levotiroxina/ 2023-03-02T09:12:08+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/03/07/nota-informativa-importante-su-ozempic-semaglutide/ 2023-03-07T16:19:42+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/03/14/sospensione-di-utilizzo-del-medicinale-lagevrio-molnupiravir/ 2023-03-14T07:45:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/03/20/nota-informativa-importante-sugli-inibitori-della-janus-chinasi/ 2023-03-20T12:16:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/03/27/monitoraggio-anticorpi-monoclonali-per-covid-19-pubblicato-il-report-n-73/ 2023-03-27T09:51:38+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/03/27/la-pegilazione-dei-farmaci-e-associata-a-reazioni-di-ipersensibilitaunanalisi-del-sistema-di-segnalazione-italiano-degli-eventi-avversi-del-farmaco/ 2023-03-27T10:23:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/12/pexels-anna-shvets-3683098-scaled.jpg https://www.farmacovigilanzasardegna.it/2023/03/27/sicurezza-ed-efficacia-di-daridorexant-nel-trattamento-dellinsonnia-una-revisione-sistematica-e-metanalisi-di-studi-randomizzati-controllati/ 2023-03-27T10:28:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/04/insonnia-26498603.jpg https://www.farmacovigilanzasardegna.it/2023/04/07/horizon-scanning-scenario-dei-medicinali-in-arrivo-aifa-pubblica-il-rapporto-2023/ 2023-04-07T07:37:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/04/13/nota-informativa-importante-su-minirin-ddavp-desmopressina/ 2023-04-13T07:39:25+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/04/13/ema-raccomanda-lapprovazione-di-bimervax-come-dose-di-richiamo-per-la-vaccinazione-covid-19/ 2023-04-13T07:56:58+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/01/close-up-picture-docter-s-hands-holding-hypodermic-syringe-scaled.jpg https://www.farmacovigilanzasardegna.it/2023/04/13/reazioni-avverse-neuropsichiatriche-in-pazienti-affetti-da-gastrointestinal-stromal-tumor-in-terapia-con-inibitori-della-tirosin-kinasi-unanalisi-dal-sistema-europeo-di-seg/ 2023-04-13T08:03:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/03/Gray1224.png https://www.farmacovigilanzasardegna.it/2023/04/13/alopecia-come-evento-avverso-emergente-degli-anticorpi-monoclonali-cgrp-serie-di-casi-valutazione-di-faers-e-revisione-della-letteratura/ 2023-04-13T08:12:53+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/05/mal-di-testa-emicrania.jpg https://www.farmacovigilanzasardegna.it/2023/04/13/aifa-pubblica-il-rapporto-luso-degli-antibiotici-in-italia-2021/ 2023-04-13T08:16:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/04/RA21_600x400-bis.jpg https://www.farmacovigilanzasardegna.it/2023/04/21/emorragia-gastrointestinale-con-gli-anticoagulanti-orali-cosa-sappiamo-attualmente/ 2023-04-21T11:07:28+00:00 https://www.farmacovigilanzasardegna.it/2023/04/21/nota-informativa-importante-su-strattera-atomoxetina/ 2023-04-21T11:14:18+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/05/04/la-gestione-terapeutica-del-danno-epatico-iatrogeno-idiosincrasico-e-tossicita-epatica-da-acetaminofene-nella-popolazione-pediatrica-una-revisione-sistematica/ 2023-05-04T13:39:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/05/tablets-health-medicine-medical.jpg https://www.farmacovigilanzasardegna.it/2023/05/04/monitoraggio-nel-mondo-reale-dei-vaccini-covid-19-una-visione-esperta-del-settore-sui-successi-le-sfide-e-le-opportunita-future/ 2023-05-04T13:46:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/05/Senza-titolo-1.jpg https://www.farmacovigilanzasardegna.it/2023/05/04/nota-informativa-importante-su-simulect-basiliximab/ 2023-05-05T09:39:28+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/05/16/antibiotici-fluorochinolonici-richiamo-alle-misure-per-ridurre-il-rischio-di-effetti-collaterali-di-lunga-durata-invalidanti-e-potenzialmente-irreversibili/ 2023-05-16T15:22:47+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/05/16/estratto-degli-highlights-della-riunione-del-prac-del-10-12-maggio-2023/ 2023-05-16T15:24:51+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/06/05/ema-raccomanda-la-revoca-dellautorizzazione-allimmissione-in-commercio-di-adakveo/ 2023-06-05T07:45:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/06/09/valutazione-della-sicurezza-farmacologica-di-ixekizumab-per-la-psoriasi-una-revisione-delle-conoscenze-attuali/ 2023-06-09T07:45:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/06/Anticuerpo_Monoclonal.png https://www.farmacovigilanzasardegna.it/2023/06/09/nota-informativa-importante-su-antibiotici-fluorochinolonici-ad-uso-sistemico-ed-inalatorio/ 2023-06-09T10:24:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/06/19/nota-informativa-importante-su-gavreto-pralsetinib/ 2023-06-19T09:47:00+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/06/23/neuropatologia-dellimmunoterapia-anti-amiloide-%ce%b2-un-caso-clinico/ 2023-06-23T07:17:31+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/06/Anticuerpo_Monoclonal.png https://www.farmacovigilanzasardegna.it/2023/07/11/livedo-reticularis-a-seguito-della-somministrazione-di-vaccino-chadox1-ncov-19-ex-vaccino-astrazeneca-un-report-di-due-casi/ 2023-07-11T06:35:06+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/07/vaccini-2.jpeg https://www.farmacovigilanzasardegna.it/2023/07/18/dichiarazione-dellema-sulla-revisione-in-corso-degli-agonisti-del-recettore-del-glp-1/ 2023-07-18T10:17:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/07/18/intelligenza-artificiale-nella-sicurezza-e-nel-metabolismo-dei-farmaci/ 2023-07-18T10:24:49+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/07/Senza-titolo.jpg https://www.farmacovigilanzasardegna.it/2023/08/01/nota-informativa-importante-su-tresiba/ 2023-08-01T10:11:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/08/16/ema-valuta-i-dati-sul-rischio-di-disturbi-del-neurosviluppo-a-seguito-di-esposizione-paterna-al-valproato-nei-mesi-precedenti-al-concepimento/ 2023-08-16T08:47:45+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2023/08/16/nota-informativa-importante-sul-dispositivo-baxject-ii-confezionato-insieme-al-medicinale-recombinate/ 2023-08-16T08:48:51+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/08/17/nota-informativa-importante-su-simponi-golimumab/ 2023-08-17T11:02:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/08/24/linee-guida-cliniche-sul-monitoraggio-e-la-gestione-degli-eventi-avversi-correlati-a-trastuzumab-deruxtecan-t-dxd-spunti-da-un-gruppo-multidisciplinare-dellasia-pacifico/ 2023-08-24T07:06:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/06/Anticuerpo_Monoclonal.png https://www.farmacovigilanzasardegna.it/2023/08/24/tossicita-cardiovascolare-degli-inibitori-del-checkpoint-immunitario-una-guida-per-i-medici/ 2023-08-24T10:15:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/tablets-3442768_960_720.jpg https://www.farmacovigilanzasardegna.it/2023/08/31/comirnaty-ema-raccomanda-lapprovazione-del-vaccino-covid-19-adattato-contro-omicron-xbb-1-5/ 2023-08-31T09:31:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/05/Senza-titolo-1.jpg https://www.farmacovigilanzasardegna.it/2023/09/01/il-crfv-pubblica-il-proprio-bollettino-semestrale-dedicato-ai-10-anni-della-farmacovigilanza-in-sardegna/ 2023-09-01T10:09:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/09/3a270771-a5e4-4e4e-b198-afcbe9e2ff2b.jpg https://www.farmacovigilanzasardegna.it/2023/09/01/aifa-pubblica-il-rapporto-nazionale-2022-luso-dei-farmaci-in-italia/ 2023-09-01T11:19:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/drug-4938120_1920.jpg https://www.farmacovigilanzasardegna.it/2023/09/05/fattori-associati-alla-sottosegnalazione-delle-reazioni-avverse-ai-farmaci-da-parte-degli-operatori-sanitari-aggiornamento-della-revisione-sistematica/ 2023-09-05T09:38:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/09/composition-paper-business-document.jpg https://www.farmacovigilanzasardegna.it/2023/09/05/ricoveri-ospedalieri-correlati-a-reazioni-avverse-ai-farmaci-in-svizzera-2012-2019-caratteristiche-mortalita-ospedaliera-e-tasso-di-segnalazione-spontanea/ 2023-09-05T09:48:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/09/Immagine1.jpg https://www.farmacovigilanzasardegna.it/2023/10/17/il-futuro-di-chatgpt-nella-farmacovigilanza/ 2023-10-17T15:29:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/10/ai.jpeg https://www.farmacovigilanzasardegna.it/2023/10/24/il-ruolo-del-farmacista-nella-segnalazione-delle-reazioni-avverse-i-dati-della-regione-sardegna/ 2023-10-24T14:42:06+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/10/logo_sifact.png https://www.farmacovigilanzasardegna.it/2023/10/24/reazioni-avverse-da-dimetilfumarato-in-unazienda-ospedaliera-della-regione-sardegna/ 2023-10-24T14:52:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/10/logo_sifact.png https://www.farmacovigilanzasardegna.it/2023/10/24/reazioni-avverse-agli-oppioidi-uno-studio-in-un-database-nazionale-di-farmacovigilanza/ 2023-10-24T15:54:38+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/05/tablets-health-medicine-medical.jpg https://www.farmacovigilanzasardegna.it/2023/10/25/trattamento-con-levotiroxina-nelle-donne-in-gravidanza-e-rischio-di-convulsioni-nei-bambini-uno-studio-di-coorte-basato-sulla-popolazione/ 2023-10-25T06:34:02+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/11/pregnancy.png https://www.farmacovigilanzasardegna.it/2023/10/26/associazione-tra-abbassamento-rigoroso-vs-indulgente-del-colesterolo-rispetto-a-esiti-cardiaci-progressione-e-complicanze-del-diabete-e-mortalita-nei-pazienti-con-diabete-trattati-con-statine-is-les/ 2023-10-26T07:36:20+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/08/I_terapia.jpg https://www.farmacovigilanzasardegna.it/2023/10/27/uno-studio-esplorativo-dellimpatto-della-segnalazione-spontanea-dei-vaccini-covid-19-sul-mascheramento-del-rilevamento-del-segnale-su-eudravigilance/ 2023-10-27T06:14:57+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/07/Senza-titolo.jpg https://www.farmacovigilanzasardegna.it/2023/11/02/comunicazione-ema-nuove-misure-per-evitare-lesposizione-al-topiramato-in-gravidanza/ 2023-11-02T14:55:04+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/11/02/cercare-un-ago-in-un-pagliaio-un-approccio-automatizzato-per-lidentificazione-delle-segnalazioni-spontanee-con-la-maggiore-utilita-clinica/ 2023-11-02T15:49:23+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/11/Techsol-Pharmacovigilance-Automation.jpg https://www.farmacovigilanzasardegna.it/2023/11/08/topiramato-nuove-restrizioni-per-prevenire-lesposizione-durante-la-gravidanza/ 2023-11-08T08:57:23+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/11/08/reazione-avverse-ai-farmaci-al-via-la-medsafetyweek-2023/ 2023-11-08T09:22:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/11/2023-Web-Banner.png https://www.farmacovigilanzasardegna.it/2023/11/08/nota-informativa-importante-su-medicinali-a-base-di-esteri-etilici-degli-acidi-omega-3/ 2023-11-08T12:02:44+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/11/10/ema-raccomanda-lapprovazione-del-vaccino-covid-19-nuvaxovid-adattato-contro-omicron-xbb-1-5/ 2023-11-10T11:10:41+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2023/11/14/thinkcascades-uno-strumento-per-identificare-le-cascate-prescrittive-clinicamente-importanti-nella-terapia-farmacologica-del-paziente-anziano/ 2023-11-14T16:17:37+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/11/palla-di-neve.jpg https://www.farmacovigilanzasardegna.it/2023/11/15/convegno-10-anni-di-farmacovigilanza-in-sardegna/ 2023-11-15T12:38:18+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/10/1.png https://www.farmacovigilanzasardegna.it/2023/11/21/iniziative-aifa-per-la-settimana-mondiale-sulluso-consapevole-degli-antibiotici/ 2023-11-21T09:39:28+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/11/WAAW_600x400.jpg https://www.farmacovigilanzasardegna.it/2023/11/30/nota-informativa-importante-su-atossisclerol/ 2023-11-30T12:13:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/11/30/il-ruolo-dei-database-sanitari-europei-per-la-valutazione-dellefficacia-della-sicurezza-e-del-valore-dei-farmaci-post-marketing-a-che-punto-e-litalia/ 2023-11-30T17:45:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/11/Real-world-evidence-service-1.1.png https://www.farmacovigilanzasardegna.it/2023/11/30/casi-di-emofilia-a-acquisita-a-seguito-dei-vaccini-covid-19-segnale-di-sicurezza-convincente-o-possibile-errore-di-segnalazione/ 2023-11-30T17:47:32+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/11/VaccinoCovid.webp https://www.farmacovigilanzasardegna.it/2023/11/28/sono-consultabili-i-dati-del-rapporto-osmed-2022-su-consumo-e-spesa-dei-farmaci-in-italia/ 2023-11-30T17:50:53+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/11/200515_OsMed_Int_600x400.jpg https://www.farmacovigilanzasardegna.it/2023/12/05/estratto-degli-highlights-della-riunione-del-prac-del-27-30-novembre-2023/ 2023-12-05T09:04:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2023/12/05/il-prac-raccomanda-misure-per-minimizzare-il-rischio-con-i-medicinali-contenenti-pseudoefedrina/ 2023-12-05T09:16:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2023/12/05/farmaci-biosimilari-in-italia-report-aifa-aggiornati-a-luglio-2023/ 2023-12-05T11:13:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2023/12/05/luso-dei-farmaci-in-italia-disponibile-la-versione-inglese-del-rapporto-osmed-2022/ 2023-12-05T11:24:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/aaa.png https://www.farmacovigilanzasardegna.it/2023/12/05/migliorare-la-sicurezza-dei-farmaci-nellunione-europea-dai-segnali-allazione/ 2023-12-05T11:50:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2023/12/05/aifa-pubblica-lelenco-dei-farmaci-innovativi/ 2023-12-05T12:32:49+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/innovazione2.jpg https://www.farmacovigilanzasardegna.it/2023/12/05/comunicazione-aifa-su-barbesaclone-25-mg/ 2023-12-05T12:35:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/Disponibilita-Barbesaclone.jpg https://www.farmacovigilanzasardegna.it/2023/12/05/reazioni-avverse-a-farmaco-nei-bambini-una-revisione-sistematica/ 2023-12-05T12:39:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/07/pd.png https://www.farmacovigilanzasardegna.it/2023/12/05/una-nuova-metodologia-di-analisi-per-lindividuazione-di-segnali-di-farmacovigilanza-nella-segnalazione-spontanea-di-eventi-avversi-su-larga-scala/ 2023-12-05T12:45:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/11/VaccinoCovid.webp https://www.farmacovigilanzasardegna.it/2023/12/19/reazioni-avverse-agli-oppioidi-uno-studio-in-un-database-nazionale-di-farmacovigilanza-2/ 2023-12-19T14:54:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/images.jpg https://www.farmacovigilanzasardegna.it/2023/12/19/corso-fad-gratuito-sullappropriatezza-prescrittiva-e-sicurezza-del-paziente-con-diabete-mellito-di-tipo-2/ 2023-12-19T15:44:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/FAD.jpg https://www.farmacovigilanzasardegna.it/2023/12/19/indagine-su-un-segnale-di-emofilia-acquisita-associata-alla-vaccinazione-covid-19-una-revisione-sistematica-del-caso/ 2023-12-19T16:52:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/globuli_rossi_full_20170525.webp https://www.farmacovigilanzasardegna.it/2023/12/22/consentire-lo-sviluppo-di-farmaci-pediatrici-in-europa-10-anni-di-regolamento-pediatrico-dellue/ 2023-12-22T09:44:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/dottore-che-fa-il-suo-lavoro-nell-ufficio-di-pediatria-scaled.jpg https://www.farmacovigilanzasardegna.it/2023/12/22/nota-informativa-importante-su-leqvio/ 2023-12-22T09:59:58+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/cuore-carriera-cardiaco-tasso-cartellone-scaled.jpg https://www.farmacovigilanzasardegna.it/2023/12/22/tanti-auguri-dal-centro-regionale-di-farmacovigilanza-della-sardegna/ 2023-12-22T12:04:22+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/Immagine-2023-12-22-130338.jpg https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/Green-And-White-Simple-Merry-Christmas-Card-1.png https://www.farmacovigilanzasardegna.it/2023/12/28/case-report-epatotossicita-e-nefrotossicita-indotte-dal-metotrexato-in-un-paziente-pediatrico-qual-e-il-ruolo-della-medicina-di-precisione-nel-2023/ 2023-12-28T10:07:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/istockphoto-1474597258-612x612-1.jpg https://www.farmacovigilanzasardegna.it/2023/12/22/farmacovigilanza-pediatrica-considerazioni-metodologiche-nella-ricerca-e-nello-sviluppo-di-farmaci-per-uso-pediatrico-un-libro-bianco-del-gruppo-di-esperti-c4c/ 2023-12-28T10:13:18+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/medico-sorridente-del-colpo-medio-che-pesa-bambino-scaled.jpg https://www.farmacovigilanzasardegna.it/2023/12/28/corso-di-perfezionamento-in-revisioni-sistematiche-e-metanalisi-per-la-produzione-di-linee-guida-evidence-based-in-ambito-sanitario/ 2023-12-28T11:29:20+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/uni_verona_wcj.png https://www.farmacovigilanzasardegna.it/2024/01/16/rischio-potenziale-di-disturbi-del-neurosviluppo-in-bambini-nati-da-uomini-trattati-con-medicinali-contenenti-valproato-il-prac-raccomanda-misure-precauzionali/ 2024-01-16T10:01:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2024/01/16/nuove-informazioni-sulla-sicurezza-per-gli-operatori-sanitari-nuove-misure-precauzionali-per-i-medicinali-contenenti-valproato/ 2024-01-16T10:05:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2024/01/16/avvio-della-revisione-di-sicurezza-sui-medicinali-a-base-di-cellule-car-t/ 2024-01-16T10:17:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2024/01/23/ema-conferma-la-raccomandazione-di-non-rinnovare-lautorizzazione-allimmissione-in-commercio-di-blenrep-un-medicinale-per-il-mieloma-multiplo/ 2024-01-23T12:59:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2024/01/25/il-crfv-pubblica-il-bollettino-semestrale-di-dicembre-2023/ 2024-01-28T21:37:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/01/bolletino.png https://www.farmacovigilanzasardegna.it/2024/01/30/misure-precauzionali-per-gestire-il-rischio-potenziale-di-disturbi-del-neurosviluppo-in-bambini-nati-da-uomini-trattati-con-medicinali-contenenti-valproato/ 2024-01-30T16:40:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2024/01/30/ema-conferma-le-misure-per-ridurre-al-minimo-il-rischio-di-effetti-collaterali-gravi-con-i-prodotti-medicinali-contenenti-pseudoefedrina/ 2024-01-30T17:15:33+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2024/02/06/lema-conferma-la-raccomandazione-di-non-rinnovare-lautorizzazione-di-translarna-per-la-distrofia-muscolare-di-duchenne/ 2024-02-06T08:42:45+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2024/02/06/farmaci-biosimilari-in-italia-laifa-pubblica-il-report-aggiornato-a-settembre-2023/ 2024-02-06T09:05:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/02/pexels-photo-4047055.webp https://www.farmacovigilanzasardegna.it/2024/02/06/il-prac-pubblica-il-work-plan-2024-focus-sullattivita-di-farmacovigilanza-e-sullinnovazione-terapeutica/ 2024-02-06T13:53:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2024/02/06/il-crfv-sardegna-pubblica-il-report-annuale-di-attivita-relativo-al-2023/ 2024-02-06T15:12:29+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/02/REPORT-segnalazione.jpg https://www.farmacovigilanzasardegna.it/2024/02/20/paxlovid-richiamo-a-reazioni-avverse-gravi-se-assunto-insieme-ad-alcuni-immunosoppressori/ 2024-02-20T11:22:32+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2024/02/20/nota-informativa-importante-su-medicinali-contenenti-valproato/ 2024-02-20T11:26:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2024/02/20/nota-informativa-importante-sui-medicinali-contenenti-pseudoefedrina/ 2024-02-20T11:33:52+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2024/03/05/%f0%9d%90%93%f0%9d%90%ab%f0%9d%90%9a%f0%9d%90%9d%f0%9d%90%a2%f0%9d%90%ad%f0%9d%90%a2%f0%9d%90%a8%f0%9d%90%a7%f0%9d%90%9a%f0%9d%90%a5-%f0%9d%90%9a%f0%9d%90%a7%f0%9d%90%9d-%f0%9d%90%a2%f0%9d%90%a7/ 2024-03-05T09:32:51+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/03/417431255_1023205632807970_3401772604763087243_n.jpg https://www.farmacovigilanzasardegna.it/2024/03/05/nota-informativa-importante-sui-medicinali-contenenti-etoposide/ 2024-03-05T15:04:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2024/03/19/estratto-degli-highlights-della-riunione-del-prac-del-4-7-marzo-2024/ 2024-03-19T07:33:34+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2024/03/19/nota-informativa-importante-sui-retinoidi-orali-acitretina-alitretinoina-e-isotretinoina/ 2024-03-19T07:45:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2024/03/19/arnas-g-brotzu-corso-ecm-farmacovigilanza-e-buon-uso-del-farmaco/ 2024-03-19T12:48:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/03/Screenshot-2024-03-19-134309.png https://www.farmacovigilanzasardegna.it/2024/03/26/nota-informativa-importante-su-medicinali-contenenti-clormadinone-acetato-etinilestradiolo/ 2024-03-26T16:09:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2024/03/26/nota-informativa-importante-su-paxlovid/ 2024-03-26T16:12:53+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2024/03/26/farmaci-biosimilari-in-italia-report-aifa-aggiornati-a-novembre-2023/ 2024-03-26T16:32:15+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/03/I_Biosimilari.jpg https://www.farmacovigilanzasardegna.it/2024/04/23/estratto-degli-highlights-della-riunione-del-prac-del-8-11-aprile-2024/ 2024-04-23T15:21:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2024/04/23/%f0%9d%90%8c%f0%9d%90%9e%f0%9d%90%9d%f0%9d%90%a2%f0%9d%90%9c%f0%9d%90%9a%f0%9d%90%ad%f0%9d%90%a2%f0%9d%90%a8%f0%9d%90%a7-%f0%9d%90%ab%f0%9d%90%9e%f0%9d%90%af%f0%9d%90%a2%f0%9d%90%9e%f0%9d%90%b0/ 2024-04-23T16:03:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/04/431186496_1038069471321586_639300716410780503_n.jpg https://www.farmacovigilanzasardegna.it/2024/05/07/gruppo-di-interesse-speciale-sugli-errori-terapeutici-della-societa-internazionale-di-farmacovigilanza-e-trends-in-international-collaboration-for-patient-safety-tendenze-della-collaborazione-interna/ 2024-05-07T09:47:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/05/pexels-photo-4021766.webp https://www.farmacovigilanzasardegna.it/2024/05/07/indicazioni-e-sicurezza-dei-nuovi-trattamenti-per-le-ibd-nel-paziente-anziano/ 2024-05-07T10:01:57+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/05/pexels-photo-3768131.jpeg https://www.farmacovigilanzasardegna.it/2024/05/07/medicinali-contenenti-risperidone-in-soluzione-orale-e-casi-di-sovradosaggio-accidentale-a-seguito-di-errori-di-somministrazione/ 2024-05-07T15:42:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2019/11/aifa-2.jpg https://www.farmacovigilanzasardegna.it/2024/05/28/il-prac-raccomanda-la-sospensione-dei-medicinali-contenenti-idrossiprogesterone-caproato-dal-mercato-europeo/ 2024-05-28T10:50:53+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/02/CHMP.jpg https://www.farmacovigilanzasardegna.it/2024/06/21/in-sardegna-sms-truffa-su-eventi-avversi-da-vaccino-covid/ 2024-06-21T08:52:25+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/06/truffa-sms-cellulare-whatsapp-2-2-2.jpg https://www.farmacovigilanzasardegna.it/2024/07/02/comunicazione-ema-sui-medicinali-a-base-di-idrossiprogesterone-caproato/ 2024-07-02T07:43:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/02/CHMP.jpg https://www.farmacovigilanzasardegna.it/2024/07/02/sorveglianza-della-sicurezza-durante-lo-sviluppo-di-un-farmaco-valutazione-comparativa-dei-regolamenti-esistenti/ 2024-07-02T08:06:44+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/pexels-photo-3873149.jpeg https://www.farmacovigilanzasardegna.it/2024/07/02/effetti-dei-farmaci-antipsicotici-nei-bambini-e-nei-giovani-su-alcuni-parametri-fisiologici-uno-studio-di-network-metanalisi/ 2024-07-02T08:07:14+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/pexels-photo-3662630.webp https://www.farmacovigilanzasardegna.it/2024/05/28/applicazione-dellintelligenza-artificiale-e-del-machine-learning-nella-rilevazione-precoce-delle-reazioni-avverse-ai-farmaci-e-della-tossicita-indotta-dai-farmaci/ 2024-07-02T08:07:37+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/05/images.jpg https://www.farmacovigilanzasardegna.it/2024/05/16/teleassistenza-intelligente-nella-farmacovigilanza-una-prospettiva-futura/ 2024-07-02T08:08:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/05/c658a6ac9e4d289a367ed1f2a07f97a4_XL.jpg https://www.farmacovigilanzasardegna.it/2024/05/16/montelukast-e-incubi-caratterizzazione-attraverso-i-dati-di-vigibase/ 2024-07-02T08:08:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/05/1200px-Montelukast_skeletal.svg_.png https://www.farmacovigilanzasardegna.it/2024/07/02/nuovo-servizio-di-consultazione-della-banca-dati-dei-farmaci-aifa/ 2024-07-02T08:31:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/NuovaBDS_it.jpg https://www.farmacovigilanzasardegna.it/2024/07/09/informazione-in-merito-al-medicinale-translarna-ataluren/ 2024-07-09T08:34:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/02/CHMP.jpg https://www.farmacovigilanzasardegna.it/2024/07/16/lestate-e-arrivata-i-suggerimenti-di-aifa-per-conservare-e-utilizzare-correttamente-i-medicinali/ 2024-07-16T09:36:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/In-estate-prenditi-cura-dei-tuoi-farmaci_600x400.jpg https://www.farmacovigilanzasardegna.it/2024/07/16/nuove-raccomandazioni-per-gli-agonisti-del-recettore-del-glp-1-per-minimizzare-il-rischio-di-aspirazione-e-di-polmonite-da-aspirazione-durante-lanestesia-generale-o-la-sedazione-profonda/ 2024-07-16T09:45:30+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2024/07/16/il-ruolo-di-isop-nel-progresso-della-farmacovigilanza-nei-paesi-a-basso-e-medio-reddito-lmic/ 2024-07-16T09:53:34+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/images.png https://www.farmacovigilanzasardegna.it/2024/07/30/aifa-pubblica-il-rapporto-vaccini/ 2024-07-30T08:33:23+00:00 https://www.farmacovigilanzasardegna.it/2024/07/30/lema-informa-dei-rischi-derivanti-dalluso-concomitante-del-medicinale-per-la-perdita-di-peso-mysimba-con-gli-oppioidi/ 2024-07-30T08:41:31+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2024/07/30/un-concetto-di-sicurezza-dei-farmaci-per-evitare-i-rischi-della-terapia-polifarmacologica-nel-trapianto-attraverso-la-gestione-individuale-della-farmacoterapia-nel-monitoraggio-terapeutico-degli-immun/ 2024-07-30T09:03:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/pexels-photo-360622.webp https://www.farmacovigilanzasardegna.it/2024/08/06/nota-informativa-importante-su-ocaliva-acido-obeticolico-2/ 2024-08-06T07:07:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2024/08/06/ema-avvia-la-revisione-di-oxbryta-medicinale-indicato-per-lanemia-falciforme/ 2024-08-06T07:10:38+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2024/08/06/adattabilita-dellia-per-la-valutazione-della-sicurezza-nella-scienza-regolatoria-un-caso-di-studio-di-lesioni-epatiche-indotte-da-farmaci/ 2024-08-06T07:22:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/08/detailed_v4@2x.jpg https://www.farmacovigilanzasardegna.it/2024/08/20/cambiare-il-paradigma-terapeutico-e-di-sviluppo-dei-farmaci-con-combinazioni-di-farmaci-biologici-e-bispecifici-come-scegliere-tra-questi-due-approcci/ 2024-08-20T09:43:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/08/Farmaci_tradizionali_e_biologici.jpg https://www.farmacovigilanzasardegna.it/2024/08/27/nota-informativa-importante-su-glatiramer-acetato/ 2024-08-27T10:01:02+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/images-AIFA-1.jpg https://www.farmacovigilanzasardegna.it/2024/08/29/linea-guida-per-la-classificazione-e-conduzione-degli-studi-osservazionali-sui-farmaci/ 2024-08-29T14:17:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/08/I_ricerca_03.jpg https://www.farmacovigilanzasardegna.it/2024/09/10/estratto-degli-highlights-della-riunione-del-prac-del-2-5-settembre-2024/ 2024-09-10T11:05:42+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2024/09/10/lema-raccomanda-misure-per-minimizzare-gli-esiti-gravi-di-un-noto-effetto-collaterale-dellantidolorifico-metamizolo/ 2024-09-10T11:08:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2024/09/17/da-aifa-una-nuova-piattaforma-digitale-per-ottimizzare-la-gestione-dei-fondi-di-farmacovigilanza/ 2024-09-17T10:14:07+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/images-AIFA-1.jpg https://www.farmacovigilanzasardegna.it/2024/09/10/il-crfv-sardegna-pubblica-il-bollettino-semestrale-di-farmacovigilanza-3/ 2024-09-19T14:35:28+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/09/Immagine-Bollettino-1.png https://www.farmacovigilanzasardegna.it/2024/09/24/seconda-giornata-regionale-della-farmacovigilanza-26-ottobre-2024/ 2024-09-24T14:41:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/09/Screenshot-2024-09-24-155048-aa.png https://www.farmacovigilanzasardegna.it/2024/10/01/farmaci-biosimilari-in-italia-report-aifa-aggiornati-a-febbraio-2024/ 2024-10-01T10:54:38+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/03/I_Biosimilari.jpg https://www.farmacovigilanzasardegna.it/2024/10/29/ema-raccomanda-la-sospensione-dellautorizzazione-allimmissione-in-commercio-di-oxbryta-medicinale-indicato-per-lanemia-falciforme/ 2024-10-29T09:24:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2024/10/29/ema-avvia-una-revisione-della-sicurezza-dei-medicinali-contenenti-finasteride-e-dutasteride/ 2024-10-29T09:28:05+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2024/10/29/nota-informativa-importante-su-oxbryta-voxelotor/ 2024-10-29T09:40:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/images-AIFA-1.jpg https://www.farmacovigilanzasardegna.it/2024/10/29/estratto-degli-highlights-della-riunione-del-prac-del-30-settembre-3-ottobre-2024/ 2024-10-29T09:42:52+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2024/09/24/lema-raccomanda-misure-per-minimizzare-gli-esiti-gravi-di-un-noto-effetto-collaterale-dellantidolorifico-metamizolo-2/ 2024-10-29T09:43:38+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2024/10/29/farmaci-line-di-aifa-avviato-il-nuovo-sistema-per-linvio-dei-quesiti/ 2024-10-29T09:58:18+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/10/I_notizie.jpg https://www.farmacovigilanzasardegna.it/2024/11/05/medsafetyweek-2024/ 2024-11-05T16:13:44+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/11/MSW24_SoMe_Its.jpg https://www.farmacovigilanzasardegna.it/2024/11/19/raccomandazioni-aggiornate-per-la-minimizzazione-dei-rischi-di-interazione-tra-il-medicinale-per-la-perdita-di-peso-mysimba-e-gli-oppioidi/ 2024-11-19T09:28:14+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/images-AIFA-1.jpg https://www.farmacovigilanzasardegna.it/2024/11/19/aifa-pubblica-il-rapporto-osmed-2023-luso-dei-farmaci-in-italia/ 2024-11-19T09:33:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/11/Screenshot-2024-11-19-103153.png https://www.farmacovigilanzasardegna.it/2024/11/19/nefrotossicita-associata-allutilizzo-di-fans-nei-bambini-ospedalizzati/ 2024-11-19T10:44:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/11/pexels-photo-5998445.webp https://www.farmacovigilanzasardegna.it/2024/11/19/eventi-avversi-maggiormente-correlati-allutilizzo-di-antibiotici-nei-pazienti-ospedalizzati/ 2024-11-19T11:04:25+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/11/pexels-photo-3873205.webp https://www.farmacovigilanzasardegna.it/2024/11/28/reazioni-avverse-a-farmaco-tra-pazienti-psichiatrici-ospedalizzati-prevalenza-gravita-prevenibilita-e-opportunitadi-intervento/ 2024-11-28T14:50:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/11/GettyImages-493991213-e1630672769340-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/11/28/reazioni-avverse-persistenti-al-gusto-allolfatto-e-alludito-relative-ai-farmaci-antibiotici/ 2024-11-28T15:38:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/11/pexels-tanya-nova-2593907-4371873-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/12/03/danno-epatico-provocato-dallutilizzo-di-fezolinetant-nelle-donne-in-menopausa/ 2024-12-03T09:22:22+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/Menopausa-e-vampate-di-calore-cause-e-suggerimenti.jpg https://www.farmacovigilanzasardegna.it/2024/12/03/doxiciclina-le-prove-attualmente-disponibili-non-supportano-il-collegamento-con-il-rischio-suicidario/ 2024-12-03T09:26:52+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/doxiciclina-farmaci-antibiotici-di-tetraciclina-classe-molecola-di-formula-scheletrico-kmrgcc.jpg https://www.farmacovigilanzasardegna.it/2024/12/03/istisan-congressi-24-c6-xxxiii-seminario-nazionale-la-valutazione-delluso-e-della-sicurezza-dei-farmaci-esperienze-in-italia/ 2024-12-03T09:40:21+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/Istisan_Congressi.png https://www.farmacovigilanzasardegna.it/2024/12/03/valutazione-della-sicurezza-degli-anticorpi-monoclonali-anti-cgrp/ 2024-12-03T10:02:33+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/images1.jpg https://www.farmacovigilanzasardegna.it/2024/12/03/farmacovigilanza-in-pediatria-6-anni-di-esperienza-del-crfv/ 2024-12-03T10:02:55+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pediatra_shu_409317970_1600x900.jpg https://www.farmacovigilanzasardegna.it/2024/12/12/gli-inibitori-di-pompa-protonica-sono-sempre-necessari/ 2024-12-12T11:21:22+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/IPP-Screenshot-2024-12-12-120623.png https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/POSTER-I.P.P-683x1024.png https://www.farmacovigilanzasardegna.it/2024/12/12/medicinali-contenenti-metamizolo-misure-importanti-per-minimizzare-gli-esiti-gravi-del-rischio-noto-di-agranulocitosi/ 2024-12-12T11:26:18+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/images-AIFA-1.jpg https://www.farmacovigilanzasardegna.it/2024/12/12/verso-il-congresso-dellinternational-society-for-pharmacoepidemiology-ispe-2026-in-italia-quali-opportunita-per-i-ricercatori-italiani/ 2024-12-12T12:12:51+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/Webinar-AIE-SIF-_-AIE-Associazione-Italiana-di-Epidemiologia.jpg https://www.farmacovigilanzasardegna.it/2024/12/12/emorragia-intracranica-indotta-da-anticoagulanti-orali-uno-studio-di-farmacovigilanza-nella-reale-pratica-clinica-nel-periodo-2008-2024/ 2024-12-12T16:18:08+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-photo-5207103.webp https://www.farmacovigilanzasardegna.it/2024/12/12/eventi-tromboembolici-associati-ai-contraccettivi-orali-combinati-uno-studio-nel-mondo-reale-basato-sul-database-del-sistema-di-segnalazione-degli-eventi-avversi-faers-della-fda/ 2024-12-12T16:25:47+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-photo-6471426.webp https://www.farmacovigilanzasardegna.it/2024/12/17/migliorare-la-segnalazione-degli-eventi-avversi-ai-farmaci-da-parte-degli-operatori-sanitari/ 2024-12-17T16:14:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/a7af6b06-0aa4-43e3-9b47-4d89ce6b67ae.png https://www.farmacovigilanzasardegna.it/2024/12/22/nota-informativa-importante-su-alofisel-darvadstrocel/ 2024-12-22T20:22:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/images-AIFA-1.jpg https://www.farmacovigilanzasardegna.it/2023/12/19/congresso-international-society-of-pharmacovigilance-isop-montreal-dal-1-al-5-ottobre-2024/ 2024-12-24T07:57:06+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/isop.jpg https://www.farmacovigilanzasardegna.it/2024/12/24/congresso-international-congresso-international-society-of-pharmacovigilance-isop-il-cairo-dal-24-al-27-ottobre-2025/ 2024-12-24T07:58:42+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/2b116cfd-afb2-4f4c-abf7-eefd2dace162.webp https://www.farmacovigilanzasardegna.it/2024/12/24/isop-mid-year-symposium-uppsala-svezia-14-15-maggio-2025/ 2024-12-24T08:11:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/uppsala_flyer.webp https://www.farmacovigilanzasardegna.it/2024/12/24/confronto-tra-le-strategie-di-farmacovigilanza-attiva-utilizzate-per-monitorare-gli-eventi-avversi-ai-farmaci-antivirali-una-revisione-sistematica/ 2024-12-24T08:46:36+00:00 https://www.farmacovigilanzasardegna.it/2024/12/24/adottare-i-criteri-stopp-start-nella-pratica-clinica-una-guida-per-i-professionisti-sanitari/ 2024-12-24T08:52:32+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-vlada-karpovich-5790813-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/12/24/collaborazione-tra-diabetologi-e-farmacisti-analisi-dellincremento-delle-segnalazioni-di-sospette-reazioni-avverse-ai-farmaci-antidiabetici/ 2024-12-24T09:14:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/2024_751-POSTER-MARRAZZO-1-Copia.png https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/2024_751-POSTER-MARRAZZO-1-724x1024.png https://www.farmacovigilanzasardegna.it/2024/12/24/utilizzo-di-farmaci-biologici-per-malattie-infiammatorie-immuno-mediate-in-pediatria/ 2024-12-24T09:29:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-julianemonarifotografia-18346362-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/12/24/nirsevimab-per-la-profilassi-del-virus-respiratorio-sinciziale-vrs-scenari-di-intervento-nella-regione-lazio/ 2024-12-24T11:55:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-emma-bauso-1183828-16579295-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/12/24/nuove-evidenze-su-statine-e-riduzione-del-rischio-cardiovascolare/ 2024-12-24T12:03:29+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-towfiqu-barbhuiya-3440682-9099821-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/12/24/ipertricosi-nei-neonati-esposti-a-minoxidil/ 2024-12-24T12:11:33+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-kelvinocta16-1973270-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/12/24/buone-feste-dal-crfv/ 2024-12-24T12:24:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/Facebook-Post-Buone-Feste-Illustrato-Naturale-Verde-Rosso.png https://www.farmacovigilanzasardegna.it/2024/12/28/fattori-predittivi-di-ospedalizzazioni-da-reazioni-avverse-ai-farmaci-nelle-persone-con-demenza-studio-retrospettivo-caso-controllo/ 2024-12-28T09:52:04+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-olly-3768114-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/12/28/farmacovigilanza-in-gravidanza-nei-paesi-a-basso-e-medio-reddito-esposizioni-esiti-e-risultati/ 2024-12-28T09:52:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-mart-production-7089333-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/12/28/esposizione-alla-desloratadina-e-incidenza-di-crisi-epilettiche-nei-bambini/ 2024-12-28T10:04:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-olly-3765115-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/12/31/rapporto-osmed-2023-in-lingua-inglese/ 2024-12-31T09:37:21+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/Immagine-medicines.png https://www.farmacovigilanzasardegna.it/2024/12/31/ema-e-intelligenza-artificiale-linee-guida-per-lutilizzo-nella-farmacovigilanza/ 2024-12-31T10:22:23+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-markusspiske-2061168-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/12/31/nuova-piattaforma-digitale-per-la-gestione-dei-fondi-di-farmacovigilanza/ 2024-12-31T10:31:00+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/images-AIFA-1.jpg https://www.farmacovigilanzasardegna.it/2024/12/31/vaccinazione-materna-contro-il-virus-respiratorio-sinciziale-efficacia-e-rischi/ 2024-12-31T11:03:55+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-daniel-reche-718241-1556671-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/12/31/miopericardite-post-vaccinazione-incidenza-nei-vaccini-covid-19-e-non-covid-19/ 2024-12-31T11:34:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-pavel-danilyuk-7108388-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/12/31/revisione-della-terapia-farmacologica-e-riduzione-dei-farmaci-inappropriati-una-posizione-del-consorzio-scientifico-italiano/ 2024-12-31T12:05:21+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/img_4069.jpg https://www.farmacovigilanzasardegna.it/2024/12/31/impatto-clinico-della-medication-review-e-del-deprescribing-nei-pazienti-anziani-ricoverati-una-revisione-sistematica-e-meta-analisi/ 2024-12-31T12:25:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-cottonbro-4661296-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/12/31/rischio-di-reazioni-avverse-cutanee-gravi-associate-agli-antibiotici-orali-comunemente-prescritti-uno-studio-caso-controllo/ 2024-12-31T12:40:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-karolina-grabowska-4210617-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/12/31/errori-di-somministrazione-dei-farmaci-nei-reparti-pediatrici/ 2024-12-31T13:03:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-cristian-rojas-84600491-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/12/31/sicurezza-a-lungo-termine-di-teriflunomide-nei-pazienti-con-sclerosi-multipla-risultati-di-studi-comparativi-prospettici-in-tre-paesi-europei/ 2024-12-31T13:25:05+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-shvetsa-4226119-scaled.jpg https://www.farmacovigilanzasardegna.it/2024/12/31/un-approccio-innovativo-alla-farmacovigilanza-scoperta-e-verifica-dei-segnali-utilizzando-dati-sanitari-elettronici/ 2024-12-31T14:17:37+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-polina-tankilevitch-5234506-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/01/09/scale-di-valutazione-della-causalita-gravita-prevenzione-e-prevedibilita-delle-reazioni-avverse-ai-farmaci-adr-una-review/ 2025-01-09T16:01:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/01/Immagine1.jpg https://www.farmacovigilanzasardegna.it/2025/01/14/nota-informativa-importante-su-veoza-fezolinetant/ 2025-01-14T09:03:45+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/images-AIFA-1.jpg https://www.farmacovigilanzasardegna.it/2025/01/14/elenco-dei-farmaci-innovativi-aifa-pubblica-laggiornamento-fino-al-31-dicembre-2024/ 2025-01-14T09:24:24+00:00 https://www.farmacovigilanzasardegna.it/2025/01/14/reazioni-avverse-ai-farmaci-nei-bambini-confronto-tra-le-segnalazioni-raccolte-in-un-progetto-di-farmacovigilanza-attiva-e-le-segnalazioni-di-adr-raccolte-spontaneamente/ 2025-01-14T09:44:30+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/01/Immagine2.png https://www.farmacovigilanzasardegna.it/2025/01/14/il-crfv-veneto-attiva-lapp-vigivrs-per-sorveglianza-nirsevimab/ 2025-01-14T09:49:02+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/01/pexels-oleksandra-18358794-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/01/21/medicinali-a-base-di-semaglutide-il-prac-sta-esaminando-il-rischio-di-una-patologia-oculare-rara/ 2025-01-21T08:13:04+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2025/01/21/chiarimenti-sulla-gestione-delle-segnalazioni-di-sospetta-reazione-avversa-adr-da-radiofarmaci/ 2025-01-21T08:25:30+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/images-AIFA-1.jpg https://www.farmacovigilanzasardegna.it/2025/01/28/sicurezza-cardiovascolare-degli-anticorpi-monoclonali-anti-cgrp-negli-anziani-o-negli-adulti-con-disabilita-affetti-da-emicrania/ 2025-01-28T09:29:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/01/pexels-karolina-grabowska-5979726-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/01/28/eventi-avversi-da-farmaci-nellassistenza-ambulatoriale/ 2025-01-28T09:56:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/01/pexels-cottonbro-7579827-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/02/04/gabapentinoidi-e-rischio-di-frattura-dellanca/ 2025-02-04T09:27:41+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/02/pexels-magda-ehlers-pexels-27376663-1.jpg https://www.farmacovigilanzasardegna.it/2025/02/04/inibitori-di-pompa-protonica-uso-e-rischio-cardiovascolare-nelle-donne-in-post-menopausa/ 2025-02-04T09:41:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/02/pexels-cottonbro-4661296-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/02/11/proteggere-i-pazienti-nellera-dellia-letica-al-centro-della-farmacovigilanza/ 2025-02-11T09:31:06+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/02/pexels-markusspiske-1921326-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/02/11/bradicardia-sintomatica-indotta-da-melatonina-in-un-giovane-uomo-sano-un-case-report/ 2025-02-11T12:55:37+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/02/pexels-feelartfeelant-1028741-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/02/19/prolungamento-del-qt-e-torsione-di-punta-indotti-da-farmaci-uno-studio-di-farmacovigilanza-real-world-che-utilizza-il-database-dellfda-adverse-event-reporting-system/ 2025-02-19T10:31:55+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/02/pexels-towfiqu-barbhuiya-3440682-9099821-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/02/19/farmaci-e-cute-una-breve-revisione-delle-reazioni-avverse-cutanee-correlate-ai-farmaci/ 2025-02-19T10:59:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/hand-3632914_640.jpg https://www.farmacovigilanzasardegna.it/2025/02/28/efficacia-e-sicurezza-degli-inibitori-della-janus-chinasi-nei-pazienti-con-vitiligine-una-revisione-sistematica-e-una-meta-analisi/ 2025-02-28T11:52:02+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/02/pexels-armin-rimoldi-5304052-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/02/28/tossicita-cardiaca-indotta-da-farmaci-e-reazioni-avverse-ai-farmaci-una-revisione-narrativa/ 2025-02-28T12:03:15+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/cuore-carriera-cardiaco-tasso-cartellone-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/03/06/eventi-avversi-psichiatrici-associati-a-semaglutide-liraglutide-e-tirzepatide-unanalisi-di-farmacovigilanza-delle-segnalazioni-di-adr-inviate-al-database-eudravigilance/ 2025-03-06T09:11:57+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/03/pexels-n-voitkevich-6942015-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/03/06/associazione-tra-inibitori-della-pompa-protonica-ipp-e-prolungamento-dellintervallo-qt-nei-pazienti-in-condizioni-critiche/ 2025-03-06T09:21:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/03/pexels-shvetsa-4421501-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/03/19/pancreatite-acuta-indotta-da-farmaci-uno-studio-di-farmacovigilanza-nel-mondo-reale-utilizzando-il-database-del-sistema-di-segnalazione-degli-eventi-avversi-della-fda/ 2025-03-19T09:09:52+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/03/pexels-tara-winstead-7723391-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/03/19/una-revisione-degli-eventi-avversi-gravi-legati-agli-agonisti-del-glp-1-nel-trattamento-del-diabete-mellito-di-tipo-2-e-dellobesita/ 2025-03-19T09:19:44+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/03/pexels-n-voitkevich-8965153-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/03/27/rischio-di-demenza-associato-a-farmaci-anticolinergici-per-la-vescica-iperattiva-in-adulti-di-eta-%e2%89%a555-anni-uno-studio-caso-controllo/ 2025-03-27T09:40:31+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/03/pexels-yaroslav-shuraev-8088898-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/03/27/uso-del-litio-in-gravidanza-differenze-in-14-nazioni/ 2025-03-27T09:45:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/11/pregnancy.png https://www.farmacovigilanzasardegna.it/2025/04/04/lema-ha-concluso-la-revisione-del-medicinale-per-la-perdita-di-peso-mysimba/ 2025-04-04T11:49:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2025/04/04/deprescrizione-nei-pazienti-anziani-in-politerapia/ 2025-04-04T12:03:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/12/pexels-cottonbro-4661296-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/04/10/multivitaminici-dopo-infarto-miocardico-in-pazienti-con-diabete-uno-studio-clinico-randomizzato/ 2025-04-10T08:44:55+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/pexels-n-voitkevich-7615414-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/04/10/formazione-dei-medici-dei-farmacisti-e-degli-infermieri-sui-pazienti-sulluso-degli-antibiotici-e-sulla-resistenza-antimicrobica-in-contesti-di-assistenza-primaria-una-revisione-sistematica-qualita/ 2025-04-10T08:49:44+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/istockphoto-109726331-612x612-1.jpg https://www.farmacovigilanzasardegna.it/2025/04/17/frequenza-del-danno-epatico-indotto-da-antibiotici-tra-pazienti-ospedalizzati/ 2025-04-17T08:35:23+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/abstract-3d-view-liver-physiology1-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/04/17/incidenza-del-danno-epatico-indotto-da-farmaci-comunemente-prescritti/ 2025-04-17T08:59:41+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/top-view-paper-holder-with-pen-bacteria-thermometer-sprays-pills-cyan-blue-background-horizontal-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/04/23/deficit-cognitivo-indotto-da-farmaci/ 2025-04-23T07:31:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/pexels-n-voitkevich-7615622-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/04/23/informazione-in-merito-al-medicinale-translarna-ataluren-2/ 2025-04-23T07:57:23+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/logo-aifa.jpeg https://www.farmacovigilanzasardegna.it/2025/04/29/nota-informativa-importante-su-opzelura-ruxolitinib/ 2025-04-29T12:01:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/logo-aifa.jpeg https://www.farmacovigilanzasardegna.it/2025/05/02/nota-informativa-importante-su-livopan/ 2025-05-02T06:37:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/logo-aifa.jpeg https://www.farmacovigilanzasardegna.it/2025/03/14/una-app-a-semaforo-targata-aifa-per-favorire-luso-appropriato-degli-antibiotici/ 2025-05-02T10:16:48+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/03/Firstline_2.png https://www.farmacovigilanzasardegna.it/2025/03/14/campagna-sulluso-consapevole-degli-antibiotici-2024/ 2025-05-02T10:20:38+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/03/Hero_Ossini_600x300.jpg https://www.farmacovigilanzasardegna.it/2025/05/09/melasma-secondario-a-farmaci-uno-studio-di-farmacovigilanza-sul-mondo-reale-del-sistema-di-segnalazione-degli-eventi-avversi-dellfda-faers/ 2025-05-09T09:07:21+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/05/melasma.jpg https://www.farmacovigilanzasardegna.it/2025/05/09/effetti-sulla-gravidanza-e-sul-bambino-in-donne-con-sclerosi-multipla-esposte-alla-terapia-con-glatiramer-acetato-uno-studio-sulla-sicurezza-esteso-a-4-anni/ 2025-05-09T10:03:59+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/05/pregnancy-6689901_960_720.jpg https://www.farmacovigilanzasardegna.it/2025/05/13/misure-per-minimizzare-il-rischio-di-pensieri-suicidari-con-i-medicinali-contenenti-finasteride-e-dutasteride/ 2025-05-13T10:15:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2025/05/15/nota-informativa-importante-su-kisqali-ribociclib/ 2025-05-15T12:09:49+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/logo-aifa.jpeg https://www.farmacovigilanzasardegna.it/2025/05/21/efficacia-e-sicurezza-di-diversi-farmaci-in-pazienti-con-carcinoma-gastrico-her2-positivo-una-meta-analisi/ 2025-05-21T11:36:51+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/05/disegno-astratto-di-anatomia-dello-stomaco-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/05/21/effetti-sulla-gravidanza-e-sul-neonato-in-donne-con-sclerosi-multipla-trattate-con-ocrelizumab/ 2025-05-21T11:39:52+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/05/donna-incinta-piedi-vicino-alla-finestra-guardando-una-foto-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/05/30/nota-informativa-importante-su-mysimba-naltrexone-bupropione/ 2025-05-30T06:59:34+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/logo-aifa.jpeg https://www.farmacovigilanzasardegna.it/2025/05/30/pseudo-iperaldosteronismo-indotto-dalla-liquirizia-un-caso-clinico/ 2025-05-30T10:03:18+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/05/istockphoto-2159298887-2048x2048-1.jpg https://www.farmacovigilanzasardegna.it/2025/06/06/riduzione-delle-cascate-prescrittive/ 2025-06-06T08:11:42+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/06/donna-che-lavora-come-medico-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/06/06/la-metformina-e-sicura-in-gravidanza-un-focus-sugli-effetti-nella-prole/ 2025-06-06T08:15:06+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/06/donna-incinta-di-vista-laterale-che-tiene-le-sue-pillole-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/06/13/20278/ 2025-06-13T08:33:42+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/06/Screenshot-2025-06-13-at-09-07-13-Antibiotici-fluorochinolonici-Antibiotici_fluorochinolonici_09.06.2025.pdf.png https://www.farmacovigilanzasardegna.it/2025/06/13/importante-aggiornamento-dal-prac-su-ozempic-rybelsus-e-wegovy-semaglutide/ 2025-06-13T09:00:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/02/CHMP.jpg https://www.farmacovigilanzasardegna.it/2025/06/18/aggiornamenti-dal-prac-sui-vaccini-contro-la-varicella/ 2025-06-18T10:44:29+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2025/06/20/individuazione-di-reazioni-avverse-gravi-da-interazioni-farmaco-farmaco-farmacocinetiche-attraverso-lanalisi-della-letteratura-e-la-verifica-delle-cartelle-cliniche-elettroniche/ 2025-06-20T10:36:34+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/06/pexels-googledeepmind-18069488-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/06/24/pubblicato-dallaifa-il-rapporto-nazionale-vaccini-2023-la-sorveglianza-post-marketing-in-italia/ 2025-06-24T10:38:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/06/Screenshot-2025-06-24-at-11-18-20-Online-il-Rapporto-Vaccini.png https://www.farmacovigilanzasardegna.it/2025/06/27/torsione-di-punta-da-interazione-farmacologica-una-analisi-di-sproporzionalita-del-sistema-di-segnalazione-degli-eventi-avversi-della-fda/ 2025-06-27T07:02:53+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/cuore-carriera-cardiaco-tasso-cartellone-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/07/02/una-analisi-di-farmacovigilanza-sulla-sicurezza-post-marketing-di-tezepelumab/ 2025-07-02T07:43:51+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/07/pexels-cottonbro-7579829-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/07/02/nota-informativa-importante-su-minirin/ 2025-07-02T08:15:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/logo-aifa.jpeg https://www.farmacovigilanzasardegna.it/2025/07/11/reazioni-avverse-ai-farmaci-negli-anziani-in-seguito-a-ricovero-ospedaliero-unanalisi-qualitativa-delle-opinioni-dei-medici-di-medicina-generale/ 2025-07-11T10:26:29+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/03/pexels-tara-winstead-7723391-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/07/11/gestione-degli-eventi-avversi-associati-agli-antibiotici/ 2025-07-11T10:41:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/07/pexels-karolina-grabowska-4021808-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/07/14/aggiornamenti-dal-comitato-per-la-valutazione-dei-rischi-in-farmacovigilanza-prac-dellema-riunione-7-10-luglio-2025-vaccini-contro-varicella-monitoraggio-ematico-clozapina-valproato-e/ 2025-07-14T08:39:22+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2025/07/21/complessita-reale-delle-cascate-prescrittive/ 2025-07-21T11:41:15+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/07/medications-1853400_960_720.jpg https://www.farmacovigilanzasardegna.it/2025/07/24/intelligenza-artificiale-nella-farmacovigilanza-una-revisione-sistematica-sulla-previsione-delle-reazioni-avverse-ai-farmaci-nei-pazienti-ospedalizzati/ 2025-07-24T08:56:33+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/07/technology-7111797_960_720.jpg https://www.farmacovigilanzasardegna.it/2025/07/17/nota-informativa-importante-su-medicinali-a-base-di-risperidone/ 2025-07-24T10:23:47+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/logo-aifa.jpeg https://www.farmacovigilanzasardegna.it/2025/07/25/esplorazione-delle-cause-di-esitazione-vaccinale-tra-adolescenti-e-genitori-risultati-di-un-progetto-di-scienza-partecipativa-europeo/ 2025-07-25T10:09:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/06/donna-che-lavora-come-medico-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/07/25/analisi-completa-delle-reazioni-avverse-associate-a-teduglutide-approfondimenti-post-marketing-e-implicazioni-sulla-sicurezza/ 2025-07-25T10:11:14+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/07/concetto-di-rappresentazione-del-dna-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/08/11/profilo-di-sicurezza-dei-fluorochinoloni/ 2025-08-11T08:19:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/08/batteri-e-pillole-virali-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/08/11/eventi-avversi-associati-ai-gepanti-unanalisi-di-farmacovigilanza-basata-sul-sistema-di-segnalazione-degli-eventi-avversi-della-fda/ 2025-08-11T08:38:18+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/08/Immagine1.jpg https://www.farmacovigilanzasardegna.it/2025/08/21/eventi-avversi-gastrointestinali-associati-agli-snri-uno-studio-di-farmacovigilanza-basato-su-faers/ 2025-08-21T10:56:31+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/05/mal-di-testa-emicrania.jpg https://www.farmacovigilanzasardegna.it/2025/08/21/eventi-avversi-cardiovascolari-e-cerebrovascolari-associati-agli-anticorpi-monoclonali-anti-vegf-intravitreali-uno-studio-di-farmacovigilanza-dellorganizzazione-mondiale-della-sanita-oms/ 2025-08-21T11:07:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/08/ChatGPT-Image-21-ago-2025-11_45_53.png https://www.farmacovigilanzasardegna.it/2025/08/21/nota-informativa-importante-su-evrysdi/ 2025-08-21T12:07:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/logo-aifa.jpeg https://www.farmacovigilanzasardegna.it/2025/08/28/nota-informativa-importante-sulla-carenza-del-medicinale-zypadhera/ 2025-08-28T08:01:06+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/logo-aifa.jpeg https://www.farmacovigilanzasardegna.it/2025/08/29/unanalisi-di-farmacovigilanza-nel-mondo-reale-del-vaccino-contro-lepatite-b-utilizzando-il-database-del-vaccine-adverse-event-reporting-system-vaers-degli-stati-uniti/ 2025-08-29T06:42:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/08/foto-vaccino-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/08/29/identificazione-dei-primi-15-farmaci-associati-allanafilassi-uno-studio-di-farmacovigilanza/ 2025-08-29T06:42:30+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/08/pexels-mart-production-7230192-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/09/02/nota-informativa-importante-su-lipidem/ 2025-09-02T09:25:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/logo-aifa.jpeg https://www.farmacovigilanzasardegna.it/2025/09/03/segnalazioni-di-sospette-reazioni-avverse-a-preparazioni-magistrali-di-cannabis-per-uso-medico-relazione-semestrale-gennaio-giugno-2025-epicentro-istituto-superiore-di-sanita/ 2025-09-03T10:14:31+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Immagine2.png https://www.farmacovigilanzasardegna.it/2021/05/22/campagna-di-sensibilizzazione-e-invito-alla-segnalazione-rivolti-ai-cittadini-nel-contesto-della-vaccinazione-di-massa-contro-covid-19/ 2025-09-03T11:46:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/05/logo_CRFVSardegna.jpg https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/07/Volantino-2022.png https://www.farmacovigilanzasardegna.it/2025/07/17/il-crfv-pubblica-il-nuovo-bollettino-semestrale-di-farmacovigilanza-2025/ 2025-09-04T08:12:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/07/Immagine1.png https://www.farmacovigilanzasardegna.it/2025/09/08/aggiornamenti-importanti-dal-comitato-per-la-valutazione-dei-rischi-in-farmacovigilanza-prac-dellema-riguardanti-levamisolo-caspofungina-crysvita-burosumab-remsima-infliximab-e-tegre/ 2025-09-08T11:10:31+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2025/09/08/nota-informativa-importante-su-victoza-liraglutide/ 2025-09-08T11:19:30+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/logo-aifa.jpeg https://www.farmacovigilanzasardegna.it/2025/09/08/nota-informativa-importante-di-sicurezza-niis-clozapina-e-rischio-di-neutropenia-e-agranulocitosi-il-prac-aggiorna-le-raccomandazioni-per-il-monitoraggio-dellemocromo/ 2025-09-08T11:30:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2025/09/10/carico-globale-delle-convulsioni-associate-agli-antidepressivi-dal-1967-al-2023-unanalisi-comparativa-del-database-internazionale-di-farmacovigilanza/ 2025-09-10T08:15:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/pexels-tara-winstead-7723388-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/09/18/divieto-di-utilizzo-lotti-medicinali-plasmaderivati-della-ditta-takeda-spa/ 2025-09-19T08:07:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Screenshot-2025-09-19-at-10-04-47-Nota-Informativa-Importante-di-Sicurezza-NIIS-%E2%80%93-Finasteride-Dutasteride-Nuove-misure-per-minimizzare-il-rischio-di-ideazione-suicidaria.png https://www.farmacovigilanzasardegna.it/2025/09/19/nota-informativa-importante-di-sicurezza-niis-finasteride-dutasteride-nuove-misure-per-minimizzare-il-rischio-di-ideazione-suicidaria/ 2025-09-19T08:08:52+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Screenshot-2025-09-19-at-10-04-47-Nota-Informativa-Importante-di-Sicurezza-NIIS-%E2%80%93-Finasteride-Dutasteride-Nuove-misure-per-minimizzare-il-rischio-di-ideazione-suicidaria.png https://www.farmacovigilanzasardegna.it/2025/09/19/campagna-europea-sulluso-responsabile-dei-farmaci-da-banco-2025/ 2025-09-19T09:25:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Immagine1.jpg https://www.farmacovigilanzasardegna.it/2025/09/26/sicurezza-ed-efficacia-del-farmaco-lecanemab-anticorpo-monoclonale-mab-anti-amiloide-per-la-malattia-di-alzheimer-in-fase-precoce-la-prospettiva-della-farmacovigilanza/ 2025-09-26T11:53:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/pexels-shvetsa-4226219-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/10/03/profilo-di-tossicita-cardiovascolare-dei-macrolidi-studiato-utilizzando-i-dati-vigibase-uno-studio-di-farmacovigilanza/ 2025-10-03T09:51:32+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/10/pexels-shvets-production-9742739-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/10/03/impatto-globale-del-danno-renale-associato-ai-vaccini-utilizzando-un-database-internazionale-di-farmacovigilanza/ 2025-10-03T10:42:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/10/pexels-shvets-production-8413337-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/09/26/uso-del-paracetamolo-in-gravidanza-confermate-le-raccomandazioni-europee/ 2025-10-06T09:24:45+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Immagine1-1.jpg https://www.farmacovigilanzasardegna.it/2025/10/08/uso-di-antipsicotici-durante-la-gravidanza-e-sicurezza-nelle-donne-in-gravidanza-e-nei-neonati/ 2025-10-08T08:41:50+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/10/pexels-pavel-danilyuk-7055918-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/10/08/analisi-dei-trends-della-segnalazione-di-eventi-avversi-gravi-associata-ai-farmaci-anti-obesita/ 2025-10-08T08:51:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/10/pexels-anntarazevich-5910763-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/10/09/nota-informativa-importante-di-sicurezza-niis-su-crysvita-burosumab/ 2025-10-09T10:36:04+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Screenshot-2025-09-19-at-10-04-47-Nota-Informativa-Importante-di-Sicurezza-NIIS-%E2%80%93-Finasteride-Dutasteride-Nuove-misure-per-minimizzare-il-rischio-di-ideazione-suicidaria.png https://www.farmacovigilanzasardegna.it/2025/10/09/nota-informativa-importante-di-sicurezza-niis-su-caspofungin/ 2025-10-09T10:42:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/images-AIFA-1.jpg https://www.farmacovigilanzasardegna.it/2025/10/16/nota-informativa-importante-di-sicurezza-niis-su-nifedicor/ 2025-10-16T07:01:55+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Screenshot-2025-09-19-at-10-04-47-Nota-Informativa-Importante-di-Sicurezza-NIIS-%E2%80%93-Finasteride-Dutasteride-Nuove-misure-per-minimizzare-il-rischio-di-ideazione-suicidaria.png https://www.farmacovigilanzasardegna.it/2025/10/17/primo-caso-di-lupus-indotto-dal-vaccino-shingrix-un-caso-clinico-e-una-revisione-della-letteratura/ 2025-10-17T08:06:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/10/pexels-artempodrez-58785101-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/10/21/sicurezza-cardiovascolare-del-romosozumab-rispetto-ai-farmaci-anti-osteoporosi-comunemente-utilizzati-nellosteoporosi-post-menopausale-una-revisione-sistematica-e-una-meta-analisi-di-rete-di-studi/ 2025-10-21T14:21:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/10/istockphoto-1202532552-612x612-1.jpg https://www.farmacovigilanzasardegna.it/2025/10/24/ema-conferma-la-sospensione-del-medicinale-per-lanemia-falciforme-oxbryta/ 2025-10-24T09:51:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2025/10/28/sorveglianza-della-sicurezza-del-vaccino-contro-il-virus-respiratorio-sinciziale-rsv-nelle-donne-in-gravidanza-uno-studio-di-farmacovigilanza-nel-mondo-reale-utilizzando-il-vaccine-adverse-event-re/ 2025-10-28T09:49:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/10/pexels-n-voitkevich-8830701-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/10/28/analisi-degli-eventi-avversi-indotti-dal-fluconazolo-basata-sul-database-faers/ 2025-10-28T09:58:33+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/10/pexels-shvetsa-3683041-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/11/03/aggiornamenti-dal-prac-riunione-27-30-ottobre-2025/ 2025-11-03T08:08:51+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2025/11/03/nota-informativa-importante-su-lenalidomide-mylan/ 2025-11-03T08:22:07+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Screenshot-2025-09-19-at-10-04-47-Nota-Informativa-Importante-di-Sicurezza-NIIS-%E2%80%93-Finasteride-Dutasteride-Nuove-misure-per-minimizzare-il-rischio-di-ideazione-suicidaria.png https://www.farmacovigilanzasardegna.it/2025/11/05/nota-informativa-importante-di-sicurezza-niis-su-levetiracetam-keppra-e-levetiracetam-ucb/ 2025-11-05T08:16:34+00:00 https://www.farmacovigilanzasardegna.it/2025/11/05/campagna-globale-per-la-sicurezza-dei-pazienti-medsafetyweek/ 2025-11-05T08:57:22+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/11/Immagine1.jpg https://www.farmacovigilanzasardegna.it/2025/11/14/eventi-avversi-associati-a-inclisiran-uno-studio-di-farmacovigilanza-nel-mondo-reale-del-sistema-di-segnalazione-degli-eventi-avversi-della-fda-faers/ 2025-11-14T11:29:47+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/11/pexels-rethaferguson-3825529-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/11/14/case-report-polmonite-indotta-da-farmaci-causata-da-moxifloxacina-e-revisione-della-letteratura/ 2025-11-14T11:33:38+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/11/pexels-shvetsa-4226207-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/11/18/analisi-predittiva-della-sicurezza-dei-vaccini-e-degli-eventi-avversi-nelle-principali-malattie-autoimmuni/ 2025-11-18T08:35:41+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/07/20944953-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/11/18/caratterizzazione-degli-eventi-avversi-orali-e-dentali-correlati-ai-farmaci-confronto-tra-letteratura-ed-etichettatura-dei-farmaci/ 2025-11-18T09:22:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/11/pexels-lilartsy-6228273-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/11/28/eventi-avversi-associati-ai-vaccini-dalla-rilevazione-alla-traduzione-in-ricerca/ 2025-11-28T10:56:14+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/09/I_vaccino_07.jpg https://www.farmacovigilanzasardegna.it/2025/12/03/nota-informativa-importante-di-sicurezza-niis-su-rybelsus-semaglutide-orale/ 2025-12-03T09:26:27+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Screenshot-2025-09-19-at-10-04-47-Nota-Informativa-Importante-di-Sicurezza-NIIS-%E2%80%93-Finasteride-Dutasteride-Nuove-misure-per-minimizzare-il-rischio-di-ideazione-suicidaria.png https://www.farmacovigilanzasardegna.it/2025/11/28/ipertrofia-gengivale-indotta-da-antagonisti-del-calcio-un-caso-clinico-e-una-revisione-della-letteratura/ 2025-12-09T11:09:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/11/pexels-cottonbro-6528864-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/12/11/nota-informativa-importante-di-sicurezza-niis-su-formulazioni-endovenose-di-acido-tranexamico/ 2025-12-11T11:02:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Screenshot-2025-09-19-at-10-04-47-Nota-Informativa-Importante-di-Sicurezza-NIIS-%E2%80%93-Finasteride-Dutasteride-Nuove-misure-per-minimizzare-il-rischio-di-ideazione-suicidaria.png https://www.farmacovigilanzasardegna.it/2025/12/11/effetti-degli-antidepressivi-sui-parametri-cardiometabolici-e-altri-parametri-fisiologici-una-revisione-sistematica-e-una-meta-analisi-di-rete/ 2025-12-11T11:48:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/12/pexels-martabranco-32210639-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/12/16/danno-renale-da-fans-unanalisi-del-mondo-reale-basata-sul-database-faers/ 2025-12-16T09:31:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2022/05/asdf.png https://www.farmacovigilanzasardegna.it/2025/12/19/nota-informativa-importante-sulla-cessazione-temporanea-della-commercializzazione-di-insulina-lispro-sanofi/ 2025-12-19T11:28:42+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Screenshot-2025-09-19-at-10-04-47-Nota-Informativa-Importante-di-Sicurezza-NIIS-%E2%80%93-Finasteride-Dutasteride-Nuove-misure-per-minimizzare-il-rischio-di-ideazione-suicidaria.png https://www.farmacovigilanzasardegna.it/2025/12/23/effetti-avversi-psichiatrici-e-psicologici-associati-a-dulaglutide-semaglutide-e-liraglutide-uno-studio-vigibase/ 2025-12-23T08:44:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/12/pexels-n-voitkevich-8965150-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/12/23/analisi-di-sicurezza-post-marketing-del-remimazolam-identificazione-di-eventi-gravi-non-etichettati/ 2025-12-23T13:02:42+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/12/pexels-shvetsa-4483332-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/01/08/tossicita-polmonare-correlata-a-trimetoprim-sulfametossazolo-revisione-dei-dati-di-farmacovigilanza/ 2026-01-08T08:20:23+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/01/pexels-cottonbro-75798291-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/01/08/tossicita-cardiovascolari-e-respiratorie-degli-anticorpi-monoclonali-nel-mieloma-multiplo-analisi-di-sproporzionalita-del-sistema-di-segnalazione-degli-eventi-avversi-della-fda/ 2026-01-08T08:35:22+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/01/3956381-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/01/13/gli-effetti-dellesposizione-al-trazodone-durante-la-gravidanza-sugli-esiti-fetali-una-revisione-sistematica/ 2026-01-13T10:11:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/01/pregnancy-6689901_960_720.webp https://www.farmacovigilanzasardegna.it/2026/01/13/sicurezza-nel-mondo-reale-dei-vaccini-contro-lhpv-una-analisi-completa-delle-segnalazioni-vaers-degli-stati-uniti-nellarco-di-18-anni/ 2026-01-13T10:14:29+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/01/pexels-franco30-8488619-scaled.jpg https://www.farmacovigilanzasardegna.it/2025/02/11/report-annuale-di-attivita-del-centro-regionale-di-farmacovigilanza-della-sardegna-2/ 2026-01-22T11:35:58+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/02/Screenshot-2025-02-11-153446.png https://www.farmacovigilanzasardegna.it/2025/01/09/il-crfv-pubblica-il-nuovo-bollettino-semestrale-di-farmacovigilanza-dicembre-2024/ 2026-01-22T11:38:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/01/Screenshot-2025-01-09-171104.png https://www.farmacovigilanzasardegna.it/2026/01/21/il-crfv-pubblica-il-secondo-bollettino-semestrale-di-farmacovigilanza-2025/ 2026-01-22T11:51:31+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/01/Immagine1.png https://www.farmacovigilanzasardegna.it/2026/01/22/analisi-di-sproporzionalita-della-sindrome-serotoninergica-associata-agli-inibitori-selettivi-della-ricaptazione-della-serotonina-ssri-unanalisi-di-farmacovigilanza-globale/ 2026-01-22T12:23:37+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2021/10/medicine.png https://www.farmacovigilanzasardegna.it/2025/12/01/corso-fad-uso-appropriato-degli-antibiotici-con-approfondimenti-ebm-progetto-nazionale-aifa-cosisifa/ 2026-01-28T10:23:53+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/12/Screenshot-2025-11-29-at-12-46-27-Locandina_FAD-Poster-A3-verticale-Locandina_FAD_antibiotici_sz_regione_compressed.pdf.png https://www.farmacovigilanzasardegna.it/2025/09/04/corso-fad-revisione-della-terapia-e-riduzione-dei-farmaci-nellanziano-progetto-nazionale-aifa-cosisifa/ 2026-01-28T10:40:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Immagine1fad.png https://www.farmacovigilanzasardegna.it/2026/01/22/cadute-correlate-ai-farmaci-proporzione-e-impatto-dei-ricoveri-ospedalieri-nei-reparti-geriatrici-sulla-prescrizione-di-farmaci-che-aumentano-il-rischio-di-caduta-frid/ 2026-01-28T10:40:18+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/03/pexels-yaroslav-shuraev-8088898-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/01/30/il-crfv-sardegna-pubblica-il-report-annuale-di-attivita-relativo-al-2025/ 2026-01-30T10:49:15+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/01/Immagine1-1.png https://www.farmacovigilanzasardegna.it/2026/01/30/identificazione-di-un-nuovo-segnale-di-dress-associato-agli-antibiotici-unanalisi-di-sproporzionalita-del-database-del-sistema-di-segnalazione-degli-eventi-avversi-della-fda-faers/ 2026-01-30T11:40:49+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/01/pexels-karola-g-5207341-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/02/05/rischio-di-gravi-malformazioni-congenite-associato-allesposizione-nel-primo-trimestre-a-farmaci-antimicotici-topici-uno-studio-su-un-ampio-database-di-richieste-di-risarcimento/ 2026-02-05T11:43:58+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/01/pregnancy-6689901_960_720.webp https://www.farmacovigilanzasardegna.it/2026/02/05/potenziali-cascate-prescrittive-dopo-la-dimissione-ospedaliera-uno-studio-di-coorte/ 2026-02-05T11:46:34+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/08/Farmaci_tradizionali_e_biologici.jpg https://www.farmacovigilanzasardegna.it/2026/02/09/nota-informativa-importante-di-qualita-su-arixtra-fondaparinux-sodico/ 2026-02-09T08:10:05+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Screenshot-2025-09-19-at-10-04-47-Nota-Informativa-Importante-di-Sicurezza-NIIS-%E2%80%93-Finasteride-Dutasteride-Nuove-misure-per-minimizzare-il-rischio-di-ideazione-suicidaria.png https://www.farmacovigilanzasardegna.it/2026/02/11/farmaci-sistemici-associati-a-maculopatia/ 2026-02-11T08:51:46+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/02/January_life_style_working_85-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/02/13/combattere-lantimicrobico-resistenza-con-la-comunicazione-sanitaria-il-progetto-pro-care-sardinia/ 2026-02-13T11:20:57+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/02/Immagine1.png https://www.farmacovigilanzasardegna.it/2026/02/17/clozapina-e-mirabegron-un-caso-clinico-di-interazione-farmacologica-con-gravi-conseguenze-in-un-paziente-geriatrico/ 2026-02-17T08:44:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/03/pexels-yaroslav-shuraev-8088898-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/02/18/fattori-di-rischio-per-reazioni-avverse-cutanee-gravi-indotte-da-farmaci-unanalisi-di-farmacovigilanza-nel-mondo-reale/ 2026-02-18T09:36:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/02/pexels-shvetsa-3786170-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/02/13/la-voce-dei-pazienti-nella-sicurezza-dei-farmaci-studio-sulla-segnalazione-in-sardegna/ 2026-02-23T10:12:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/02/Post-Instagram-Locandina-progetto-sottosegnalazione.png https://www.farmacovigilanzasardegna.it/2025/12/19/nota-informativa-importante-di-sicurezza-niis-su-carbamazepina-tegretol-20-mg-ml-sciroppo/ 2026-02-25T10:47:31+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/images-AIFA-1.jpg https://www.farmacovigilanzasardegna.it/2026/02/26/valutazione-degli-effetti-avversi-attribuiti-alla-terapia-con-statine-nelle-etichette-dei-prodotti-una-meta-analisi-di-studi-clinici-randomizzati-in-doppio-cieco/ 2026-02-26T07:58:45+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/02/pexels-n-voitkevich-7615407-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/02/26/effetti-epatici-potenziale-danno-epatico-indotto-da-farmaci-e-altre-considerazioni-sulla-sicurezza-epatica-della-terapia-con-cellule-t-del-recettore-antigenico-chimerico-car-t-nella-nuova-era-di-in/ 2026-02-26T11:13:37+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/02/iffany-cells-8718453_1920.png https://www.farmacovigilanzasardegna.it/2026/03/06/anemia-emolitica-e-trombocitosi-indotte-da-cefoperazone-sulbactam-segnalazione-di-un-caso-e-revisione-della-letteratura/ 2026-03-06T09:34:25+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/03/pexels-karola-g-4046997-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/03/09/vaccinare-bimbi-e-bimbe-una-scelta-consapevole/ 2026-03-09T12:39:42+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/03/Immagine3.png https://www.farmacovigilanzasardegna.it/2026/03/13/analisi-della-sproporzionalita-e-del-tempo-di-insorgenza-dellaumento-di-peso-indotto-da-farmaci-utilizzando-il-database-giapponese-sugli-eventi-avversi-da-farmaci-jader/ 2026-03-13T09:15:23+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/03/pexels-pixabay-47073-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/03/17/lagenzia-italiana-del-farmaco-aifa-pubblica-il-position-paper-medicina-di-precisione-e-appropriatezza-della-prescrizione-farmacologica/ 2026-03-17T10:32:51+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/03/Immagine1.png https://www.farmacovigilanzasardegna.it/2026/03/17/aggiornamenti-importanti-dal-comitato-per-la-valutazione-dei-rischi-in-farmacovigilanza-prac-riunione-del-9-12-marzo-2026/ 2026-03-19T11:58:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2026/03/25/review-sulle-lesioni-epatiche-indotte-dalla-medicina-tradizionale-cinese/ 2026-03-25T09:51:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/03/Immagine1-1.png https://www.farmacovigilanzasardegna.it/2026/03/25/nota-informativa-importante-di-sicurezza-niis-su-remsima-infliximab/ 2026-03-25T09:58:17+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Screenshot-2025-09-19-at-10-04-47-Nota-Informativa-Importante-di-Sicurezza-NIIS-%E2%80%93-Finasteride-Dutasteride-Nuove-misure-per-minimizzare-il-rischio-di-ideazione-suicidaria.png https://www.farmacovigilanzasardegna.it/2026/03/27/come-difendersi-dalle-false-cure-miracolose-le-raccomandazioni-di-aifa/ 2026-03-27T10:37:53+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/03/Firefly_Gemini-Flash_Come-difendersi-dalle-false-cure-miracolose-le-raccomandazioni-di-AIFA-364258.png https://www.farmacovigilanzasardegna.it/2026/03/31/modelli-di-previsione-del-rischio-di-reazioni-avverse-ai-farmaci-in-ambito-pediatrico-una-revisione-esplorativa/ 2026-03-31T08:06:06+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/03/pexels-polina-tankilevitch-3873213-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/03/31/metodi-di-apprendimento-automatico-per-la-previsione-di-eventi-avversi-da-farmaci-una-revisione-sistematica/ 2026-03-31T08:11:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/03/medical-banner-with-doctor-holding-tablet-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/04/02/ema-raccomanda-la-restrizione-delle-indicazioni-terapeutiche-del-medicinale-tecovirimat-siga/ 2026-04-02T10:09:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2026/04/10/rischio-di-sanguinamento-gastrointestinale-associato-a-specifici-ssri-e-snri-una-revisione-sistematica-e-metanalisi/ 2026-04-10T07:59:52+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/05/tablets-health-medicine-medical.jpg https://www.farmacovigilanzasardegna.it/2026/04/10/luso-di-semaglutide-e-associato-alla-degenerazione-della-giunzione-neuromuscolare-negli-anziani-affetti-da-diabete-mellito-di-tipo-ii/ 2026-04-10T08:08:32+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/02/pexels-cottonbro-4661296-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/04/14/luso-degli-antibiotici-in-italia-rapporto-nazionale-anno-2024/ 2026-04-14T10:49:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/04/Screenshot-2026-04-14-at-12-01-25-Rapporto-antibiotici_2024.qxp_Layout-1-Rapporto_Antibiotici_2024.pdf.png https://www.farmacovigilanzasardegna.it/2026/04/14/aggiornamenti-importanti-dal-prac-riunione-del-7-10-aprile-2026-ontozry-cenobamato-nuove-informazioni-di-sicurezza-su-casi-di-danno-epatico/ 2026-04-16T08:00:08+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/EMA-LOGO-NUOVO.jpg https://www.farmacovigilanzasardegna.it/2026/04/21/rischio-di-eventi-avversi-cardiaci-neuropsichiatrici-e-muscoloscheletrici-con-levotiroxina-revisione-sistematica/ 2026-04-21T08:07:19+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/04/pexels-deise-elen-2149983761-31406906-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/04/21/cascate-prescrittive-una-revisione-a-ombrello-e-una-revisione-sistematica-aggiornata/ 2026-04-21T09:38:52+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/04/pexels-tara-winstead-7723397-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/04/23/dalle-terapie-a-taglia-unica-alle-cure-su-misura-la-rivoluzione-della-medicina-di-precisione/ 2026-04-23T07:33:03+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/04/Screenshot-2026-04-23-at-09-09-13-Dossier_stampa_Prescrittomica.pdf.png https://www.farmacovigilanzasardegna.it/2026/04/30/colite-indotta-da-ocrelizumab-analisi-di-disproporzionalita-da-vigibase-casi-clinici-e-revisione-della-letteratura/ 2026-04-30T08:26:00+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/04/pexels-tima-miroshnichenko-6010935-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/05/05/aifa-richiama-alluso-corretto-del-paracetamolo-con-particolare-attenzione-ai-casi-di-sovradosaggio-intenzionale-negli-adolescenti/ 2026-05-05T11:53:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Screenshot-2025-09-19-at-10-04-47-Nota-Informativa-Importante-di-Sicurezza-NIIS-%E2%80%93-Finasteride-Dutasteride-Nuove-misure-per-minimizzare-il-rischio-di-ideazione-suicidaria.png https://www.farmacovigilanzasardegna.it/2026/05/08/valutazione-completa-della-sicurezza-di-ribociclib-unanalisi-nel-mondo-reale-utilizzando-il-database-del-sistema-di-segnalazione-degli-eventi-avversi-della-fda-faers/ 2026-05-08T10:00:57+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/05/pexels-marcio-carvalho-1334537412-28879524-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/05/12/nota-informativa-importante-di-sicurezza-niis-su-ontozry-cenobamato/ 2026-05-12T08:00:24+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Screenshot-2025-09-19-at-10-04-47-Nota-Informativa-Importante-di-Sicurezza-NIIS-%E2%80%93-Finasteride-Dutasteride-Nuove-misure-per-minimizzare-il-rischio-di-ideazione-suicidaria.png https://www.farmacovigilanzasardegna.it/2026/05/12/associazione-tra-luso-regolare-di-paracetamolo-o-ibuprofene-e-rischio-di-insorgenza-di-calcolosi-renale/ 2026-05-13T07:46:00+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/10/pexels-shvetsa-3683041-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/05/18/nota-informativa-importante-su-restrizione-delle-indicazioni-terapeutiche-del-medicinale-tecovirimat-siga/ 2026-05-18T07:14:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/09/Screenshot-2025-09-19-at-10-04-47-Nota-Informativa-Importante-di-Sicurezza-NIIS-%E2%80%93-Finasteride-Dutasteride-Nuove-misure-per-minimizzare-il-rischio-di-ideazione-suicidaria.png https://www.farmacovigilanzasardegna.it/2026/05/18/segnalazioni-di-dipendenza-da-pregabalin-astinenza-tendenze-suicide-e-psicosi-unanalisi-di-disproporzione-del-database-australiano-degli-eventi-avversi/ 2026-05-18T08:04:32+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/05/Pregabalin-a-Narcotic-6-Copia.jpg https://www.farmacovigilanzasardegna.it/2026/05/22/nuovi-farmaci-per-il-diabete-di-tipo-2-e-lobesita-guida-aifa-per-un-uso-consapevole/ 2026-05-22T06:46:51+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/05/Card_Farmaci_Antidiabetici_600-400.jpeg https://www.farmacovigilanzasardegna.it/2026/05/29/cannabinoidi-e-interazioni-farmacocinetiche-tra-farmaci-decifrare-i-rischi/ 2026-05-29T08:38:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/05/cannabis-farmaci-interazioni-696x500-1.jpg https://www.farmacovigilanzasardegna.it/2026/05/29/aifa-introduce-un-pittogramma-ufficiale-per-le-note-informative-importanti-di-sicurezza-niis/ 2026-05-29T09:10:52+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/05/pittogramma_600x400.png https://www.farmacovigilanzasardegna.it/2026/06/05/e-sempre-meglio-di-piu-che-di-meno-la-riduzione-della-terapia-farmacologica-per-migliorare-gli-esiti-clinici-dei-pazienti-una-serie-di-casi/ 2026-06-05T10:27:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/03/pexels-yaroslav-shuraev-8088898-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/06/05/collaborazione-tra-medico-di-medicina-generale-e-farmacista-per-migliorare-la-riduzione-della-prescrizione-di-psicofarmaci-sedativi-e-anticolinergici-nei-pazienti-anziani-in-politerapia-nellambito/ 2026-06-05T10:46:04+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/06/sabinevanerp-hand-3667015_1920.jpg https://www.farmacovigilanzasardegna.it/2026/06/11/corso-fad-ecm-valutazione-critica-della-letteratura-sui-farmaci-oncologici-progetto-nazionale-aifa-cosisifa/ 2026-06-11T08:42:30+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/06/Immagine1.png https://www.farmacovigilanzasardegna.it/2026/06/11/cardiotossicita-associata-agli-agenti-antifungini-unanalisi-di-farmacovigilanza-del-sistema-di-segnalazione-degli-eventi-avversi-della-fda/ 2026-06-11T10:14:14+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2023/12/cuore-carriera-cardiaco-tasso-cartellone-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/06/15/aggiornamenti-dal-prac-riguardanti-valproatovaccino-ixchiq-e-tavneos-riunione-8-11-giugno-2026/ 2026-06-15T09:15:25+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/06/PRAC.jpg https://www.farmacovigilanzasardegna.it/2026/06/15/nota-informativa-importante-di-qualita-su-evrysdi-risdiplam/ 2026-06-15T09:20:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/06/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2026/06/22/uso-di-antidepressivi-da-parte-della-madre-e-del-padre-prima-e-durante-la-gravidanza-e-rischio-di-disturbi-dello-sviluppo-neurologico-nella-prole-una-revisione-sistematica-e-una-metanalisi/ 2026-06-22T09:08:22+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/01/pregnancy-6689901_960_720.webp https://www.farmacovigilanzasardegna.it/2026/06/22/dati-reali-su-adesione-efficacia-e-sicurezza-del-vaccino-contro-il-virus-respiratorio-sinciziale-rsv-negli-anziani-una-revisione-sistematica-e-una-metanalisi/ 2026-06-22T09:27:51+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/06/pexels-artempodrez-5878481-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/06/30/identificazione-basata-sulla-farmacovigilanza-ed-esplorazione-dei-meccanismi-molecolari-sottostanti-della-parodontite-correlata-a-farmaci/ 2026-06-30T10:28:43+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/06/pexels-ignacio-pereira-240566698-12309026-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/06/30/ema-raccomanda-la-revoca-dellautorizzazione-allimmissione-in-commercio-per-tavneos-avacopan/ 2026-06-30T10:51:51+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/06/PRAC.jpg https://www.farmacovigilanzasardegna.it/2026/07/07/analisi-della-sicurezza-degli-agonisti-del-recettore-glp-1-galenici-uno-studio-di-farmacovigilanza-utilizzando-il-sistema-di-segnalazione-degli-eventi-avversi-della-fda/ 2026-07-07T09:59:56+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/07/clker-free-vector-images-tablets-309742_1920.png https://www.farmacovigilanzasardegna.it/2026/07/09/rischi-clinici-della-fluvoxamina-e-farmacovigilanza-nel-mondo-reale-una-analisi-di-disproporzione-basata-sui-dati-faers/ 2026-07-09T07:42:07+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/07/vacho-jar-2338584-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/07/13/aggiornamenti-dal-prac-riunione-6-9-luglio-2026/ 2026-07-13T11:52:29+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/06/PRAC.jpg https://www.farmacovigilanzasardegna.it/2026/07/16/anticoagulanti-orali-e-sanguinamento-gastrointestinale-approfondimenti-di-farmacovigilanza-dal-database-del-sistema-di-segnalazione-degli-eventi-avversi-della-fda-faers/ 2026-07-16T07:35:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/coagulazione1.jpg https://www.farmacovigilanzasardegna.it/2026/07/20/nota-informativa-importante-di-sicurezza-niis-su-tavneos-avacopan/ 2026-07-20T06:43:48+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/07/Screenshot-2026-07-20.png https://www.farmacovigilanzasardegna.it/2026/07/21/identificazione-degli-effetti-tossici-fatali-nella-terapia-con-inibitori-dei-checkpoint-immunitari-utilizzando-dati-di-farmacovigilanza-real-world-e-apprendimento-automatico/ 2026-07-21T08:24:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/07/pexels-cottonbro-7580248-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/07/24/nota-informativa-importante-di-qualita-su-vyvgart/ 2026-07-24T08:02:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/07/Immagine2.png https://www.farmacovigilanzasardegna.it/2026/07/27/demenza-indotta-da-farmaci-unanalisi-di-farmacovigilanza-del-database-faers/ 2026-07-27T08:42:50+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/07/pexels-yaroslav-shuraev-8088907-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/07/28/ulcera-cutanea-indotta-da-farmaci-analisi-di-farmacovigilanza-nel-mondo-reale-basata-sul-sistema-di-segnalazione-degli-eventi-avversi-della-fda/ 2026-07-28T08:19:38+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/07/pexels-shvetsa-37861701-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/08/18/nota-informativa-importante-di-sicurezza-niis-su-bendamustina-accord/ 2026-08-18T06:54:20+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/07/Screenshot-2026-07-20.png https://www.farmacovigilanzasardegna.it/2026/08/18/nota-informativa-importante-di-sicurezza-niis-su-medicinali-contenenti-desogestrel-ed-etonogestrel/ 2026-08-18T06:58:55+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/07/Screenshot-2026-07-20.png https://www.farmacovigilanzasardegna.it/2026/08/18/nota-informativa-importante-di-sicurezza-niis-su-litfulo-ritlecitinib/ 2026-08-18T07:02:42+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/07/Screenshot-2026-07-20.png https://www.farmacovigilanzasardegna.it/2026/08/20/efficacia-e-sicurezza-di-galcanezumab-nel-mondo-reale-per-il-trattamento-dellemicrania-una-revisione-sistematica-e-una-metanalisi/ 2026-08-20T09:09:54+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/08/pexels-martabranco-32418224-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/08/28/valutazione-della-sicurezza-post-marketing-dei-farmaci-contro-la-stitichezza-uno-studio-di-farmacovigilanza-nel-mondo-reale-basato-sul-database-faers/ 2026-08-28T10:14:08+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2024/07/pexels-photo-3873149-1.jpeg https://www.farmacovigilanzasardegna.it/2026/08/28/atrofia-muscolare-associata-agli-agonisti-del-recettore-del-peptide-1-simile-al-glucagone-uno-studio-osservazionale-basato-sulla-popolazione/ 2026-08-28T10:22:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/08/pexels-maksgelatin-5995061-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/08/28/osteoporosi-osteopenia-indotta-da-farmaci-unanalisi-di-farmacovigilanza-utilizzando-il-database-del-sistema-di-segnalazione-degli-eventi-avversi-della-fda/ 2026-08-28T11:51:26+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/10/istockphoto-1202532552-612x612-1.jpg https://www.farmacovigilanzasardegna.it/2026/09/02/analisi-di-sicurezza-dei-gepanti-per-il-trattamento-dellemicrania-uno-studio-di-farmacovigilanza-utilizzando-il-database-del-sistema-di-segnalazione-degli-eventi-avversi-della-fda-faers/ 2026-09-02T10:18:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/08/Immagine1.jpg https://www.farmacovigilanzasardegna.it/2026/09/03/miocardite-pericardite-non-infettiva-indotta-da-farmaci-uno-studio-di-farmacovigilanza-nel-mondo-reale-basato-sul-database-faers/ 2026-09-03T06:58:40+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/09/pexels-n-voitkevich-7615405-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/09/07/aggiornamenti-dal-prac-riunione-del-31-agosto-3-settembre-2026-revisione-di-sicurezza-dei-medicinali-contenenti-ferro-per-via-iniettiva/ 2026-09-07T07:15:50+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/06/PRAC.jpg https://www.farmacovigilanzasardegna.it/2026/09/09/il-crfv-pubblica-il-primo-bollettino-semestrale-di-farmacovigilanza-2026/ 2026-09-09T09:37:08+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/09/Immagine-bollettino-1-2026.png https://www.farmacovigilanzasardegna.it/2026/03/06/analisi-sistematica-e-indagine-meccanicistica-degli-eventi-avversi-cardiaci-associati-ai-coniugati-anticorpo-farmaco-utilizzando-il-database-faers/ 2026-09-09T09:38:45+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/03/high-angle-pills-beside-virus-bacteria1-scaled.jpg https://www.farmacovigilanzasardegna.it/2026/09/10/dati-del-mondo-reale-e-infezioni-multiresistenti-come-possiamo-sfruttare-i-dati-del-mondo-reale-per-migliorare-lesito-clinico-dei-pazienti-con-le-nuove-combinazioni-di-beta-lattamici-e-beta-lattami/ 2026-09-10T07:46:01+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2025/04/istockphoto-109726331-612x612-1.jpg https://www.farmacovigilanzasardegna.it/2026/09/14/corso-fad-ecm-antimicrobico-resistenza-lapproccio-one-health-progetto-nazionale-aifa-cosisifa/ 2026-09-14T11:25:59+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/09/immagine-one-health.png https://www.farmacovigilanzasardegna.it/2026/09/18/efficacia-e-sicurezza-di-ofatumumab-nella-pratica-clinica-reale-nella-sclerosi-multipla-recidivante-uno-studio-di-coorte-multicentrico/ 2026-09-18T10:34:32+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2026/09/pexels-silverkblack-39192355-scaled.jpg